var title_f16_27_16816="2D TTE Parasternal short axis pap muscles";
var content_f16_27_16816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view at the level of the papillary muscles and mitral valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 171px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal short axis view from a transthoracic echocardiogram recorded in systole at the level of the papillary muscles (left) and&nbsp;mitral valve (right) shows the anterior and posterior leaflets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16816=[""].join("\n");
var outline_f16_27_16816=null;
var title_f16_27_16817="Osteosarcoma knee CT";
var content_f16_27_16817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteosarcoma of the distal femur",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 215px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal CT image of the knee demonstrates a large mass involving the distal femoral metaphysis, with lobulated soft tissue component and bony destruction, consistent with osteosarcoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16817=[""].join("\n");
var outline_f16_27_16817=null;
var title_f16_27_16818="Patient information: Dengue fever (The Basics)";
var content_f16_27_16818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/42/27298\">",
"         Patient information: Staying healthy when you travel (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/2/16421\">",
"         Patient information: General travel advice (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dengue fever (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dengue-fever-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16292573\">",
"      <span class=\"h1\">",
"       What is dengue fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dengue fever is an infection caused by 1 of the 4 viruses called the &ldquo;dengue viruses.&rdquo; They are related to each other, but are not exactly the same. Getting sick from 1 dengue virus does not protect a person from the others. A person can get dengue fever more than once.",
"     </p>",
"     <p>",
"      Dengue fever is spread by mosquitoes that carry dengue viruses. People who live in areas where these mosquitoes are common have the highest risk of infection. These areas include southern Asia, Central and South America, and the Caribbean. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16292588\">",
"      <span class=\"h1\">",
"       What are the symptoms of dengue fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms usually happen 4 to 7 days after a bite from a mosquito that carries dengue virus. But they can happen up to 2 weeks later. Symptoms usually last 5 to 7 days.",
"     </p>",
"     <p>",
"      Dengue fever symptoms are different for each person. They can be mild or severe. They can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Pain behind the eyes",
"       </li>",
"       <li>",
"        Joint and muscle pain",
"       </li>",
"       <li>",
"        Feeling tired, sometimes for days to weeks",
"       </li>",
"       <li>",
"        Rash &ndash; This can be flat or have small bumps. It might be itchy. A rash is more common in people who have not been infected with a dengue virus before.",
"       </li>",
"       <li>",
"        Stomach problems, such as nausea, vomiting, and diarrhea",
"       </li>",
"       <li>",
"        Cough, sore throat, and stuffy nose &ndash; The throat might look red.",
"       </li>",
"       <li>",
"        Small purple spots on the skin or bowel movements that look black",
"       </li>",
"       <li>",
"        Red eyes",
"       </li>",
"       <li>",
"        Swollen glands",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Children and younger people often have less severe symptoms. People who had dengue fever in the past and get infected with a different dengue virus have the highest risk of severe symptoms.",
"     </p>",
"     <p>",
"      A person with severe dengue fever might:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Have bad belly pain",
"       </li>",
"       <li>",
"        Get bruises without bumping into anything &ndash; The person might also have small purple spots on the skin.",
"       </li>",
"       <li>",
"        Vomit blood",
"       </li>",
"       <li>",
"        Get nosebleeds",
"       </li>",
"       <li>",
"        Have black bowel movements",
"       </li>",
"       <li>",
"        Have seizures &ndash; A person who has a seizure might pass out or move or behave strangely. For example, he or she might shake or fall down. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A woman might also have bleeding between her menstrual periods.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16292603\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you live in a country where dengue fever is common, see a doctor or nurse if you have any of the symptoms.",
"     </p>",
"     <p>",
"      If you used to live in a country where dengue fever is common, and recently went back for a visit, see a doctor or nurse if you have any symptoms of dengue fever. You might have had an infection when you lived there, and gotten infected again on your visit. People who visit these countries often should also see a doctor or nurse if they have symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16292618\">",
"      <span class=\"h1\">",
"       Is there a test for dengue fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. A doctor might be able to tell if you have dengue fever by doing an exam and learning about the symptoms. He or she can also do blood tests. These tests can find the dengue viruses. It sometimes takes 2 different tests to tell for sure.",
"     </p>",
"     <p>",
"      In countries where dengue fever is common, you might not get a blood test. But doctors can still treat the symptoms if they think you have it. &nbsp; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16292633\">",
"      <span class=\"h1\">",
"       How is dengue fever treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no treatment for the virus that causes dengue fever, but doctors can treat the symptoms. Very sick people can be treated in the hospital. Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood transfusions &ndash; If the infection causes severe bleeding, doctors can give the person blood that someone else has given to the hospital.",
"       </li>",
"       <li>",
"        Getting fluids through a tube called an &ldquo;IV&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people are at risk of getting sicker from dengue fever than other people. These people include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pregnant women",
"       </li>",
"       <li>",
"        Babies",
"       </li>",
"       <li>",
"        Older people",
"       </li>",
"       <li>",
"        People who are obese",
"       </li>",
"       <li>",
"        People who have diabetes, kidney failure, or certain blood diseases",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These people might need to go to the hospital if they get dengue fever. Doctors can watch for severe symptoms and treat them if they happen. People who live alone or far from a doctor&rsquo;s office or hospital might also need to stay in the hospital. That way, they can be treated right away if they get very sick. &nbsp;",
"     </p>",
"     <p>",
"      People who are not as sick can usually rest at home. If you have dengue fever, you might need to see a doctor or nurse every day until you get better. The doctor or nurse can do blood tests and check your blood pressure. These checkups are important because dengue fever can cause serious bleeding. Doctors can look to see if this is happening, and treat it early if it does.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16292648\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If the doctor says you do not need to go to the hospital, you can stay home, rest, and drink plenty of fluids. You can also take",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;) to relieve fever and aches.",
"     </p>",
"     <p>",
"      Do not take",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      or NSAIDs, such as",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;) or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (brand name: Aleve&reg;). These medicines can increase the risk of bleeding in people with dengue fever. Never give aspirin or medicines that contain aspirin to children younger than 18. In children, aspirin can cause a serious problem called Reye syndrome.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16292663\">",
"      <span class=\"h1\">",
"       Can dengue fever be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The best way to prevent dengue fever is to avoid the mosquitoes that carry it. Not all countries where dengue fever is common control mosquitoes well. But you can lower your chances of getting dengue fever if you live or travel there. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Stay inside during the day, when the mosquitoes that carry dengue fever are active. Buildings with screens and air conditioning are safest.",
"       </li>",
"       <li>",
"        Wear shoes, long-sleeved shirts, and long pants when you go outside.",
"       </li>",
"       <li>",
"        Wear bug spray or cream that contains DEET when you are outside. Check the label to make sure.",
"       </li>",
"       <li>",
"        Drain any standing water near your home, such as wading pools and buckets. Mosquitoes breed in standing water.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There is no vaccine for dengue fever yet.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16292678\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"       Patient information: Staying healthy when you travel (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       Patient information: General travel advice (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/27/16818?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83159 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16818=[""].join("\n");
var outline_f16_27_16818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16292573\">",
"      What is dengue fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16292588\">",
"      What are the symptoms of dengue fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16292603\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16292618\">",
"      Is there a test for dengue fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16292633\">",
"      How is dengue fever treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16292648\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16292663\">",
"      Can dengue fever be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16292678\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_27_16819="Lead line gums";
var content_f16_27_16819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lead line in the gums of a patient with occupational lead poisoning",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows a \"lead line\" in the region between the teeth and gingiva of a patient with lead poisoning due to occupational exposure (automobile radiator repair). The dark areas (arrows) represent deposition of insoluble lead following interaction with sulfur-containing metabolites produced by bacteria in these gingival pockets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photograph provided by Stephen A Landaw, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16819=[""].join("\n");
var outline_f16_27_16819=null;
var title_f16_27_16820="Steroid induced acne";
var content_f16_27_16820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Steroid induced acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy;2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16820=[""].join("\n");
var outline_f16_27_16820=null;
var title_f16_27_16821="Decision tree axial SpA primary";
var content_f16_27_16821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80964%7ERHEUM%2F59693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80964%7ERHEUM%2F59693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Approach to the diagnosis of axial spondyloarthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 535px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The figure shows an algorithmic approach to the diagnosis of spondyloarthropathy (SpA) in clinical practice. This approach was developed for the primary care physician or others with limited experience in evaluating patients for early inflammatory disease of the spine. Percentages in brackets indicate the probability of axial SpA before (pretest probability) and after a test has been performed (post-test probability).",
"    <div class=\"footnotes\">",
"     * Suspicions for SpA could be the presence of several other clinical features.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004; 63:535. Copyright &copy; 2004 BMJ Publishing Group.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Decision tree on diagnosing axial spondyloarthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 585px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Starting point is the presence or absence of inflammatory back pain (IBP) in patients presenting with chronic back pain. In general, for making the diagnose of axial SpA a disease probability &gt;90 percent is suggested.",
"    <div class=\"footnotes\">",
"     * Dependent on which features are positive.",
"     <br>",
"      &bull; If the probability of disease exceeds 90 percent we consider the diagnosis axial SpA as definite. If the probability is 80 to 90 percent, we consider the diagnosis as probable.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rudwaleit M, van der heijde D, Khan MA, et al. How to diagnosis axial spondyloarthritis early. Ann Rheum Dis 2004; 63:535. Copyright &copy; 2004 BMJ Publishing Group.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16821=[""].join("\n");
var outline_f16_27_16821=null;
var title_f16_27_16822="Extralobar sequestration at 32 weeks of gestation";
var content_f16_27_16822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Extralobar sequestration at 32 weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound demonstrates a left lower lobe echogenic mass (A) with a systemic feeding vessel demonstrated with Doppler examination (B). A subtle high signal mass (arrow) is noted on magnetic resonance coronal (C) and sagittal (D) images. A linear low signal line through the mass represents a systemic feeding vessel. Postnatal CT images (E) axial and (F) sagittal reformatted image at 1 month of age demonstrate an enhancing mass (arrow) in left lower lobe region, abutting diaphragm with a feeding vessel originating from the descending aorta. A draining vein was identified coursing into the portal vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy I Bulas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16822=[""].join("\n");
var outline_f16_27_16822=null;
var title_f16_27_16823="Information and educational resources for occupational and environmental health issues in the United States";
var content_f16_27_16823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Information and educational resources for occupational and environmental health issues in the United States",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16823/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16823/contributors\">",
"     Rose H Goldman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16823/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16823/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16823/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16823/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/27/16823/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of resources are available for clinicians and patients who need additional information about occupational and environmental health issues. Resources related to organizations in the United States are outlined here. An overview of occupational and environmental health is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=see_link\">",
"     \"Overview of occupational and environmental health\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     KEY TOPICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Emergency preparedness and response",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to on-line information, a number of these sites have information that can be downloaded to a handheld device.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CDC: Emergency Preparedness and Response (",
"      <a class=\"external\" href=\"file://emergency.cdc.gov/\">",
"       file://emergency.cdc.gov/",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Institute of Occupational and Environmental Health (NIOSH): Occupational Safety and Health topics - Emergency Preparedness and Response (",
"      <a class=\"external\" href=\"file://www.cdc.gov/niosh/topics/emergency.html\">",
"       file://www.cdc.gov/niosh/topics/emergency.html",
"      </a>",
"      ). Includes tip sheets for numerous types of hazards, including chemical, natural, radiation, etc.",
"     </li>",
"     <li>",
"      American College of Physicians: Online bioterrorism resources (",
"      <a class=\"external\" href=\"file://www.acponline.org/bioterro/\">",
"       www.acponline.org/bioterro/",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      ACP Guide for Chemical Terrorism Identification (",
"      <a class=\"external\" href=\"file://www.acponline.org/bioterro/chem_terr.pdf\">",
"       www.acponline.org/bioterro/chem_terr.pdf",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      United States Nuclear Regulatory Commission: What to do for a radiological emergency (",
"      <a class=\"external\" href=\"file://www.nrc.gov/about-nrc/emerg-preparedness.html\">",
"       www.nrc.gov/about-nrc/emerg-preparedness.html",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Federal Emergency Management Agency (FEMA): Plan Ahead (",
"      <a class=\"external\" href=\"file://www.fema.gov/plan/index.shtm\">",
"       www.fema.gov/plan/index.shtm",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pandemics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Influenza Pandemic (",
"      <a class=\"external\" href=\"file://www.pandemicflu.gov/index.html\">",
"       www.pandemicflu.gov/index.html",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      American College of Physicians: Adult Immunization information (",
"      <a class=\"external\" href=\"file://www.acponline.org/clinical_information/resources/adult_immunization\">",
"       www.acponline.org/clinical_information/resources/adult_immunization",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      World Health Organization: Pandemic Preparedness (",
"      <a class=\"external\" href=\"file://www.who.int/influenza/preparedness/pandemic/en/\">",
"       www.who.int/influenza/preparedness/pandemic/en/",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dampness, mold and health effects",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CDC: mold and health, and guidelines about clean-up. Links to other sites. (",
"      <a class=\"external\" href=\"file://www.cdc.gov/mold/\">",
"       www.cdc.gov/mold/",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      WHO: Damp and Mould: Health risks, prevention and remedial action (short brochure-good patient hand out, 2009). (",
"      <a class=\"external\" href=\"file://www.euro.who.int/__data/assets/pdf_file/0003/78636/Damp_Mould_Brochure.pdf\">",
"       file://www.euro.who.int/__data/assets/pdf_file/0003/78636/Damp_Mould_Brochure.pdf",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      WHO Regional Office of Europe, Protecting health from home damp and mould (",
"      <a class=\"external\" href=\"file://www.euro.who.int/__data/assets/pdf_file/0017/43325/E92645.pdf\">",
"       file://www.euro.who.int/__data/assets/pdf_file/0017/43325/E92645.pdf",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Board on Health Promotion and Disease Prevention (HPDP), Institute of Medicine (IOM). Damp indoor spaces and health. The National Academies Press, 2004. Free executive summary also available on website. (",
"      <a class=\"external\" href=\"file://www.nap.edu/openbook.php?isbn=0309091934\">",
"       www.nap.edu/openbook.php?isbn=0309091934",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Storey E, Dangman KH, Schenck P, et al. Guidance for Clinicians on the Recognition and Management of Health Effects Related to Mold Exposure and Moisture Indoors. University of Connecticut Health Center Division of Occupational and Environmental Medicine, 2004. (",
"      <a class=\"external\" href=\"file://oehc.uchc.edu/clinser/MOLD GUIDE.pdf\">",
"       file://oehc.uchc.edu/clinser/MOLD%20GUIDE.pdf",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      EPA: \"A Brief Guide to mold, moisture, and your home,\" 2010. (",
"      <a class=\"external\" href=\"file://www.epa.gov/iaq/molds/moldguide.html\">",
"       www.epa.gov/iaq/molds/moldguide.html",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      American College of Occupational and Environmental Medicine (ACOEM). Position Statement",
"      <br/>",
"      Adverse Human Health Effects Associated with Molds in the Indoor Environment, February 2011. (",
"      <a class=\"external\" href=\"file://www.acoem.org/AdverseHumanHealthEffects_Molds.aspx\">",
"       file://www.acoem.org/AdverseHumanHealthEffects_Molds.aspx",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Finding information about chemicals",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPA Integrated Risk Information System - The Integrated Risk Information System (IRIS) is an electronic database containing information on human health effects from various substances. This database provides concise information on individual chemicals (",
"      <a class=\"external\" href=\"file://cfpub.epa.gov/ncea/iris/index.cfm\">",
"       file://cfpub.epa.gov/ncea/iris/index.cfm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Agency for Toxic Substances and Disease Registry (",
"      <a class=\"external\" href=\"file://www.atsdr.cdc.gov/\">",
"       file://www.atsdr.cdc.gov/",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Medical Management Guidelines (MMGs) for Acute Chemical Exposures (",
"      <a class=\"external\" href=\"file://www.atsdr.cdc.gov/mmg/index.asp\">",
"       www.atsdr.cdc.gov/MMG/index.asp",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Toxicological Profiles (",
"      <a class=\"external\" href=\"file://www.atsdr.cdc.gov/toxprofiles/index.asp\">",
"       file://www.atsdr.cdc.gov/toxprofiles/index.asp",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      United States National Library of Medicine: Toxicology Data Network (Toxnet) (",
"      <a class=\"external\" href=\"file://toxnet.nlm.nih.gov/\">",
"       file://toxnet.nlm.nih.gov",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chemical Information Specialized Information Services (",
"      <a class=\"external\" href=\"file://sis.nlm.nih.gov/chemical.html\">",
"       file://sis.nlm.nih.gov/chemical.html",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      ChemIDplus: Chemical dictionary database of compounds of biomedical and regulatory interest-with links to articles (",
"      <a class=\"external\" href=\"file://chem.sis.nlm.nih.gov/chemidplus/\">",
"       file://chem.sis.nlm.nih.gov/chemidplus/",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Collaborative on Health and the Environment Database: Summarizes links between chemical contaminants and approximately 180 human diseases or conditions. A collaboration among University of California at San Francisco, Natural Resources Defense Fund, and Science and Environmental Health Network (",
"      <a class=\"external\" href=\"file://database.healthandenvironment.org/index.cfm\">",
"       file://database.healthandenvironment.org/index.cfm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Toxicology Program, US Department of Health and Human Services: 12th Report on Carcinogens (",
"      <a class=\"external\" href=\"file://ntp.niehs.nih.gov/?objectid=03C9AF75-E1BF-FF40-DBA9EC0928DF8B15\">",
"       file://ntp.niehs.nih.gov/?objectid=03C9AF75-E1BF-FF40-DBA9EC0928DF8B15",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Report on Human Exposure to Environmental Chemicals (",
"      <a class=\"external\" href=\"file://www.cdc.gov/exposurereport/\">",
"       www.cdc.gov/exposurereport/",
"      </a>",
"      ) (last update 2012)",
"     </li>",
"     <li>",
"      UCSF Program on Reproductive Health and the Environment. &ldquo;Toxic Matters.&rdquo; (",
"      <a class=\"external\" href=\"file://www.prhe.ucsf.edu/prhe/toxicmatters.html\">",
"       file://www.prhe.ucsf.edu/prhe/toxicmatters.html",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      CDC : Identification and Management of Lead Exposure in Pregnant women",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf\">",
"       file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      NIOSH Pocket Guide &mdash; The NPG is intended as a source of general industrial hygiene information on several hundred chemicals and classes for workers, employers, and occupational health professionals. The NPG does not contain an analysis of all pertinent data; rather, it presents key information and data in abbreviated or tabular form for chemicals or substance groupings (eg, cyanides, fluorides, manganese compounds) that are found in the work environment.&nbsp;(",
"      <a class=\"external\" href=\"file://www.cdc.gov/niosh/npg\">",
"       www.cdc.gov/niosh/npg",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      NIOSH Registry of Toxic Effects of Chemical Substances (",
"      <a class=\"external\" href=\"file://www.cdc.gov/niosh/rtecs\">",
"       www.cdc.gov/niosh/rtecs",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     UNITED STATES GOVERNMENT AGENCIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Agency for Toxic Substances and Disease Registry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Agency for Toxic Substances and Disease Registry (ATSDR) is a division within the Public Health Service of the US Department of Health and Human Services. It is dedicated to preventing exposure and adverse human health effects associated with hazardous substances from waste sites, unplanned releases, and other sources of pollution in the environment. It publishes comprehensive Toxicological Profiles on a variety of agents. Each profile includes a short \"Public Health Statement\" in nontechnical language about that agent. The ATSDR website also provides fact sheets on critical hazards, including Tox FAQ (Toxicology Frequently Asked Questions) and case Studies in Environmental Medicine, which are useful for teaching.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.atsdr.cdc.gov/\">",
"     www.atsdr.cdc.gov",
"    </a>",
"    , for Tox FAQ:",
"    <a class=\"external\" href=\"file://www.atsdr.cdc.gov/toxfaqs/index.asp\">",
"     www.atsdr.cdc.gov/toxfaqs/index.asp",
"    </a>",
"    , (888) 42-ATSCR, (888) 422-8737, email:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Centers for Disease Control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control (CDC) provide information on birth defects, developmental disabilities, and environmental hazards and health effects.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cdc.gov\">",
"     www.cdc.gov",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Travelers' Health Information",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://wwwn.cdc.gov/travel/default.aspx\">",
"     wwwn.cdc.gov/travel/default.aspx",
"    </a>",
"   </p>",
"   <p>",
"    CDC's Yellow Book: Health Information for International Travel 2012 (",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm\">",
"     file://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     National Center for Environmental Health",
"    </span>",
"    &nbsp;&mdash;&nbsp;This site has chemical exposure information, advice for managing hazardous materials incidents, as well as a list of emergency preparedness links.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cdc.gov/nceh/default.htm\">",
"     www.cdc.gov/nceh/default.htm",
"    </a>",
"    , CDC-INFO, 800-CDC-INFO, 800-232-4636, TTY 888-232-6348, 24",
"    <span class=\"nowrap\">",
"     Hours/Day,",
"    </span>",
"    E-mail:",
"    <a class=\"external\" href=\"mailto:cdcinfo@cdc.gov\">",
"     cdcinfo@cdc.gov",
"    </a>",
"    , CDC Emergency Response: 770-488-7100, for state and local health department assistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Air Pollution and Respiratory Health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Includes information and links to numerous other sites.",
"   </p>",
"   <p>",
"    (",
"    <a class=\"external\" href=\"file://www.cdc.gov/healthyplaces/healthtopics/airpollution.htm\">",
"     www.cdc.gov/healthyplaces/healthtopics/airpollution.htm",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     United States Consumer Product Safety Commission",
"    </span>",
"    &nbsp;&mdash;&nbsp;This independent federal regulatory agency helps to reduce the risk of injury or death from consumer products. It can be contacted to inquire about or report unsafe products and has a special section for children's safety.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cpsc.gov/\">",
"     www.cpsc.gov",
"    </a>",
"    , (800) 638-2772",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     United States Environmental Protection Agency (EPA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the sites below, the EPA site has many links on their home page to sites with useful information.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.epa.gov/\">",
"     www.epa.gov",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13861797\">",
"    <span class=\"h3\">",
"     Air Quality Tools for Schools Kit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instructions for obtaining a free copy of the kit are available",
"    <a class=\"external\" href=\"file://www.epa.gov/nscep/ordering.html\">",
"     online",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.epa.gov/iaq/schools/actionkit.html\">",
"     www.epa.gov/iaq/schools/actionkit.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     EPA Integrated Risk Information System",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see above). The IRIS site also includes a useful glossary of terms.",
"   </p>",
"   <p>",
"    <br/>",
"    <a class=\"external\" href=\"file://ofmpub.epa.gov/sor_internet/registry/termreg/searchandretrieve/glossariesandkeywordlists/search.do?details=&amp;glossaryname=iris glossary\">",
"     file://ofmpub.epa.gov/sor_internet/registry/termreg/searchandretrieve/glossariesandkeywordlists/search.do?details=&amp;glossaryName=IRIS%20Glossary",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     EPA Toxics Release Inventory Program",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Toxic Chemical Release Inventory (TRI) is an annual compilation on estimated releases into the environment of over 300 toxic chemicals. The data can be searched by zip code and other geographic values, by name of company, and by chemical substance.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.epa.gov/tri\">",
"     www.epa.gov/tri",
"    </a>",
"    , (800) 424-9346",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     EPA Safe Drinking Water Hotline",
"    </span>",
"    &nbsp;&mdash;&nbsp;This hotline provides information to health professionals and the public, makes referrals, and distributes EPA publications.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://water.epa.gov/\">",
"     file://water.epa.gov/",
"    </a>",
"    , (800) 426-4791",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     EPA Office of Children's Health Protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;This office works with states to develop programs to address children's environmental health issues, and provides information and resources to individuals and communities who are interested in working to protect the health of children.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://yosemite.epa.gov/ochp/ochpweb.nsf/content/homepage.htm\">",
"     file://yosemite.epa.gov/ochp/ochpweb.nsf/content/homepage.htm",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     EPA Toxicity and Exposure Assessment for Children's Health (TEACH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This searchable database contains overviews of scientific literature in the field of children's environmental health.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.epa.gov/teach/\">",
"     www.epa.gov/teach/",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     EPA Recognition and Management of Pesticide Poisonings",
"    </span>",
"    &nbsp;&mdash;&nbsp;This revised handbook, available at no charge on line, covers 1500 pesticide products addressing toxicology, signs and symptoms of poisoning, and treatment. Useful book published in 1999; updates on CDC website.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.epa.gov/pesticides/safety/healthcare/handbook/handbook.htm\">",
"     www.epa.gov/pesticides/safety/healthcare/handbook/handbook.htm",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Federal Citizen Information Center",
"    </span>",
"    &nbsp;&mdash;&nbsp;This agency provides",
"   </p>",
"   <p>",
"    useful information about product safety and a current list of product recalls.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.pueblo.gsa.gov/\">",
"     www.pueblo.gsa.gov",
"    </a>",
"    , (888) 878-3256",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Federal Emergency Management Agency (FEMA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;FEMA, part of the US Department of Homeland Security, has a primary mission to reduce the loss of life and property and protect people in the United States from all hazards, including natural disasters, acts of terrorism, and other man-made disasters, by leading and supporting a risk- based, comprehensive emergency management system of preparedness, protection, response, recovery, and mitigation.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.fema.gov/index.shtm\">",
"     www.fema.gov/index.shtm",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"mailto:FEMA-Correspondence-Unit@dhs.gov\">",
"     FEMA-Correspondence-Unit@dhs.gov",
"    </a>",
"    , 1 (800) 621-FEMA (3362)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Federal Motor Carrier Safety Administration (FMCSA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FMCSA was established as a separate administration within the US Department of Transportation on January 1, 2000, pursuant to the Motor Carrier Safety Improvement Act of 1999. The FMCSA's primary mission is to reduce crashes, injuries, and fatalities involving large trucks and buses. Physicians interface with FMCSA when performing Department of Transportation (DOT) exams.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.fmcsa.dot.gov/registration-licensing/registration-licensing.htm\">",
"     file://www.fmcsa.dot.gov/registration-licensing/registration-licensing.htm",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     United States Department of Housing and Urban Development",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is the regulatory agency for detecting and eliminating lead-based paint in housing.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.hud.gov/\">",
"     www.hud.gov",
"    </a>",
"    , (800) HUD-S-FHA, (800) 483-7342",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Household Products Database",
"    </span>",
"    &nbsp;&mdash;&nbsp;The household products database of the National Library of Medicine is based on the Consumer Product Information Database &copy; 2001 by DeLima Associates. This database links over 4000 consumer brands to health effects from Material Safety Data Sheets (MSDS) provided by the manufacturers, and it allows scientists and consumers to research products based on chemical ingredients.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://householdproducts.nlm.nih.gov/\">",
"     file://householdproducts.nlm.nih.gov",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Indoor Air Quality Information Clearinghouse (EPA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This department answers inquiries about indoor air quality and the health effects of indoor air pollution.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.epa.gov/iaq/index.html\">",
"     www.epa.gov/iaq/index.html",
"    </a>",
"    (800) 438-4318",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     National Radon Hotline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Safety Council's hotline provides information about radon and test kits.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.epa.gov/radon/hotlines.html\">",
"     www.epa.gov/radon/hotlines.html",
"    </a>",
"    ; (800) SOS-RADON, (800) 767-7236",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Occupational Safety and Health Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Occupational Safety and Health Administration (OSHA) has a national office within the Department of Labor, as well as regional offices all over the country. OSHA is responsible for creating and enforcing workplace safety and health regulations. OSHA offers publications about their regulations, occupational diseases, and fact sheets. Worksite inspections can be triggered by the complaint of a current worker.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.osha.gov/\">",
"     www.osha.gov",
"    </a>",
"    , for emergencies, dial the national office: (800) 321-OSHA, (800) 321-6742",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     National Institute for Occupational Safety and Health",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Institute for Occupational Safety and Health (NIOSH) is part of the CDC and is responsible for conducting research and making recommendations for the prevention of work-related illnesses and injuries. NIOSH can provide information about substance toxicity by telephone inquiry and also has \"criteria documents\" summarizing research and information on various workplace hazards. NIOSH performs Health Hazard Evaluations of workplaces. The site also provides an online pocket guide to chemical hazards (intended to be usable on a Pocket PC), and information on respirators, musculoskeletal disorders, and issues related to health care workers.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cdc.gov/niosh/\">",
"     www.cdc.gov/niosh/",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     NIOSH Technical Inquiries",
"    </span>",
"   </p>",
"   <p>",
"    1-800-CDC-INFO (1-800-232-4636)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     NIOSH International Chemical Safety Card project",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NIOSH International Chemical Safety Card Project (ICSC) summarizes essential health and safety information on chemicals in non-technical language for their use at the \"shop floor\" level by workers and employers.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cdc.gov/niosh/ipcs/icstart.html\">",
"     www.cdc.gov/niosh/ipcs/icstart.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     NIOSH Respirators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information and links to sites providing information about the proper selection of respirators, respirator types, and care of respirators.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cdc.gov/niosh/topics/respirators/\">",
"     www.cdc.gov/niosh/topics/respirators/",
"    </a>",
"    &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     National Institute of Environmental Health Sciences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Institute of Environmental Health Sciences (NIEHS), a component within the National Institutes of Health (NIH) Department of Health and Human Services, is engaged in multidisciplinary biomedical research programs in environmental health, prevention, and intervention efforts. It offers some environmental Fact Sheets and pamphlets on selected topics such as pesticides, endocrine disruptors, and electromagnetic fields (EMF). It also allows free access to its journal, Environmental Health Perspectives, which published high quality research articles, reviews, and case reports on a variety of environmental health and medicine issues.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.niehs.nih.gov/\">",
"     www.niehs.nih.gov",
"    </a>",
"    , (919) 541-3345",
"   </p>",
"   <p>",
"    Environmental Health Perspectives,",
"    <a class=\"external\" href=\"file://www.ehponline.org/\">",
"     www.ehponline.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     National Library of Medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Library of Medicine and the NIH have compiled a database of household products that is very well organized and easy to use, enabling one to browse and search products, ingredients, and Material Safety Data Sheets (MSDS) to get information about health effects. It also offers information by trade name.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://householdproducts.nlm.nih.gov/\">",
"     file://householdproducts.nlm.nih.gov",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     National Pesticide Information Center",
"    </span>",
"    &nbsp;&mdash;&nbsp;This Center is a cooperative effort between Oregon State University and the United States EPA, and it provides chemical, health, and environmental information on more than 600 pesticide active ingredients used in over 50,000 products.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://npic.orst.edu/\">",
"     file://npic.orst.edu",
"    </a>",
"    , 1-800-858-7378",
"   </p>",
"   <p>",
"    (7:30 AM to 3:30 PM PST), or email npic@ace.orst.edu",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Pesticide Action Network Pesticides Database - current toxicity and regulatory information for pesticides",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.pesticideinfo.org/\">",
"     www.pesticideinfo.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     UNITED STATES ARMED FORCES WEBSITES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Armed Services",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Post-Deployment Health: Deployment Health Clinical Center",
"    </span>",
"    &nbsp;&mdash;&nbsp;Website to assist health care providers in the delivery of employment and post-deployment healthcare (",
"    <a class=\"external\" href=\"file://www.pdhealth.mil/\">",
"     www.pdhealth.mil/",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Force Health Protection &amp; Readiness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provides health and safety and other information developed by the military for the military personal, and for clinicians taking care of armed forces",
"    <span class=\"nowrap\">",
"     (file://fhp.osd.mil/)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Army Wounded Soldier and Family Hotline",
"    </span>",
"    &nbsp;&mdash;&nbsp;(800)",
"    984-8523, 7 am - 7 pm EST Monday through Friday",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.armymedicine.army.mil/wsfh/index.html\">",
"     file://www.armymedicine.army.mil/wsfh/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     NONGOVERNMENTAL SOURCES AND PROFESSIONAL SOCIETIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     American Board of Preventive Medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Board certification in Occupational and Environmental Medicine is through the American Board of Preventive Medicine. This site provides information about training and certification requirements, as well as residency training programs.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.theabpm.org/\">",
"     www.theabpm.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     American College of Occupational and Environmental Medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Occupational and Environmental Medicine (ACOEM) is the world's largest organization of occupational and environmental physicians. It sponsors education conferences; publishes the Journal of Occupational and Environmental Medicine, a newsletter, position papers and guidelines; maintains a directory of physicians who are board-certified in occupational-environmental medicine and members of the college located in regions throughout the United States; and provides lists of useful references -- all of this information is found on the website.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.acoem.org/\">",
"     www.acoem.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     American Academy of Pediatrics",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.aap.org\">",
"     www.aap.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h3\">",
"     AAP Children's Health Topics: Environmental health",
"    </span>",
"    &nbsp;&mdash;&nbsp;This website offers information on a number of topics relevant to pediatric environmental health and also provides AAP policy statements on key topics such as lead exposure, air pollution, indoor molds, and mercury. There is also access to and ordering information for the AAP Handbook of Pediatric Environmental Health:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www2.aap.org/visit/cmte16.htm\">",
"     www2.aap.org/visit/cmte16.htm",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Association of Occupational and Environmental Clinics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Association of Occupational and Environmental Clinics (AOEC) is a network of nonprofit, academically-affiliated clinics and occupational medicine physicians throughout the United States. Practitioners can contact the AOEC clinics and refer patients for assistance in diagnosis, management, and prevention of occupational or environmentally-related illnesses. The website contains information and listings of the AOEC clinics, Pediatric Environmental Health Specialty Units, and educational materials in OEM.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.aoec.org/\">",
"     www.aoec.org",
"    </a>",
"    , (888) 347-2632",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     American Conference of Governmental Industrial Hygienists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Originally founded as an organization of government-related industrial hygienists, the American Conference of Governmental Industrial Hygienists (ACGIH) membership comprises all practitioners of industrial health, occupational health, environmental health, and safety. ACGIH is well known for its paperback book, Documentation of Threshold Limit Values, which includes more than 700 chemical substances, 15 agents, and 36 Biologic Exposure Limits. ACGIH also has a publications clearinghouse and a directory of their membership of occupational health specialists.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.acgih.org/\">",
"     www.acgih.org",
"    </a>",
"    , (513) 742-2020",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     American Association of Occupational Health Nurses",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is the professional organization for occupational health nurses, and the internet site contains information about conferences, training and other educational materials.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.aaohn.org/\">",
"     www.aaohn.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     American Cancer Society",
"    </span>",
"    &nbsp;&mdash;&nbsp;This association offers information on cancer prevention, detection, diagnosis and treatment. State and local branches sponsor stop smoking programs.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cancer.org/\">",
"     www.cancer.org",
"    </a>",
"    , (800) ACS-2345",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     American Lung Association",
"    </span>",
"    &nbsp;&mdash;&nbsp;This association provides stop smoking programs and information on radon and asbestos.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.lungusa.org/\">",
"     www.lungusa.org",
"    </a>",
"    , 1-800-LUNGUSA",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Greater Boston Physicians for Social Responsibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;A resource and action site for children's health environmental health issues. The site offers educational materials, including \"In Harm&rsquo;s Way,\" a resource about environmental toxins and infant and child development, can be downloaded from the website:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.psr.org/chapters/boston/health-and-environment/\">",
"     file://www.psr.org/chapters/boston/health-and-environment/",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h2\">",
"     Children's Environmental Health Network",
"    </span>",
"    &nbsp;&mdash;&nbsp;This Network concentrates on education, research, and policy in children's environmental health issues. The Network developed and produced the book, Resource Guide on Children's Environmental Health, with funding from private and governmental sources in 1997. The book includes listings with descriptions of government and private organizations, data sources, and a useful search index.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cehn.org/\">",
"     www.cehn.org",
"    </a>",
"    , (202) 543-4033",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h2\">",
"     Environmental health journals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available free online.",
"   </p>",
"   <p>",
"    Environmental Health Perspectives: Journal of peer-reviewed research and news on the impact of the environment on human health, published by the National Institute of Environmental Health Sciences. (",
"    <a class=\"external\" href=\"file://ehponline.org/\">",
"     file://ehponline.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    Environmental Health: An open access journal with experienced academically affiliated editors in which you also see article reviews and commentary. (",
"    <a class=\"external\" href=\"file://www.ehjournal.net/\">",
"     www.ehjournal.net",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    Environmental Health News: This resource provides an excellent source of aggregated daily up-to-date information focusing on news, new science, new reports, and \"hot topics\" in environmental health. You may opt to receive a daily email, \"Above the Fold\", that will keep you informed on media coverage of environmental health concerns, issues, policy, and events. (",
"    <a class=\"external\" href=\"file://www.environmentalhealthnews.org/\">",
"     www.environmentalhealthnews.org/",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h2\">",
"     Transportation Medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources for health care professionals involved in the medical evaluation of workers in the transportation industries. Presented By OccuMedix, Inc, and Natalie P. Hartenbaum, MD, MPH, FACOEM, Chief Medical Officer. This site contains a wealth of information concerning doing examinations related to transportation and interpreting medical regulations.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.occumedix.com/\">",
"     file://www.occumedix.com",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h1\">",
"     TEACHING MATERIALS IN OCCUPATIONAL AND ENVIRONMENTAL HEALTH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h2\">",
"     Association of Occupational and Environmental Clinics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Described earlier, AOEC also maintains a lending library of teaching slide shows on occupational and environmental health topics, and it also has some modules available on the website.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.aoec.org/resources.htm\">",
"     www.aoec.org/resources.htm",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h2\">",
"     Center for Health and the Global Environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mission of the Center for Health and the Global Environment (CHGE) at Harvard School of Public Health is to educate students, faculty, physicians, other health professions, scientists, environmentalists, policy makers, media, and the general public about the potential human health consequences of global environmental change. The website contains educational resources on such topics as climate change, biodiversity, and human health.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://chge.med.harvard.edu/\">",
"     file://chge.med.harvard.edu",
"    </a>",
"    , (617) 384-8530.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2750 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16823=[""].join("\n");
var outline_f16_27_16823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      KEY TOPICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Emergency preparedness and response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pandemics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dampness, mold and health effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Finding information about chemicals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      UNITED STATES GOVERNMENT AGENCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Agency for Toxic Substances and Disease Registry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Centers for Disease Control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Travelers' Health Information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - National Center for Environmental Health",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Air Pollution and Respiratory Health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      United States Consumer Product Safety Commission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      United States Environmental Protection Agency (EPA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13861797\">",
"      - Air Quality Tools for Schools Kit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - EPA Integrated Risk Information System",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - EPA Toxics Release Inventory Program",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - EPA Safe Drinking Water Hotline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - EPA Office of Children's Health Protection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - EPA Toxicity and Exposure Assessment for Children's Health (TEACH)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - EPA Recognition and Management of Pesticide Poisonings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Federal Citizen Information Center",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Federal Emergency Management Agency (FEMA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Federal Motor Carrier Safety Administration (FMCSA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      United States Department of Housing and Urban Development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Household Products Database",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Indoor Air Quality Information Clearinghouse (EPA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      National Radon Hotline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Occupational Safety and Health Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      National Institute for Occupational Safety and Health",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - NIOSH Technical Inquiries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - NIOSH International Chemical Safety Card project",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - NIOSH Respirators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      National Institute of Environmental Health Sciences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      National Library of Medicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      National Pesticide Information Center",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Pesticide Action Network Pesticides Database - current toxicity and regulatory information for pesticides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      UNITED STATES ARMED FORCES WEBSITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Armed Services",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Post-Deployment Health: Deployment Health Clinical Center",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Force Health Protection &amp; Readiness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Army Wounded Soldier and Family Hotline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      NONGOVERNMENTAL SOURCES AND PROFESSIONAL SOCIETIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      American Board of Preventive Medicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      American College of Occupational and Environmental Medicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      American Academy of Pediatrics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      - AAP Children's Health Topics: Environmental health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Association of Occupational and Environmental Clinics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      American Conference of Governmental Industrial Hygienists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      American Association of Occupational Health Nurses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      American Cancer Society",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      American Lung Association",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Greater Boston Physicians for Social Responsibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      Children's Environmental Health Network",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      Environmental health journals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      Transportation Medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      TEACHING MATERIALS IN OCCUPATIONAL AND ENVIRONMENTAL HEALTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      Association of Occupational and Environmental Clinics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      Center for Health and the Global Environment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=related_link\">",
"      Overview of occupational and environmental health",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_27_16824="Gastrointestinal disorders in athletes";
var content_f16_27_16824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gastrointestinal disorders in athletes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16824/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16824/contributors\">",
"     John H Kwon, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16824/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16824/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16824/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16824/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/27/16824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes are vulnerable to a variety of gastrointestinal disorders, some of which are related to physiologic changes resulting from exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Physiologic changes include alterations in enteric nervous system activity, circulating gut hormone levels, intestinal blood flow, nutrient and electrolyte absorption, secretion and gut motility [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the most frequently observed gastrointestinal disorders that occur in athletes, focusing mainly on endurance athletes (",
"    <a class=\"graphic graphic_table graphicRef66975 \" href=\"UTD.htm?1/5/1115\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies suggest that gastrointestinal (GI) problems are common among athletes, the incidence ranging from 20 to 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. The majority of endurance athletes experience GI symptoms during training or races; running appears to be more problematic than cycling. Among athletes competing in mixed endurance events (such as triathlons), the majority of symptoms occur during the running portion. The following illustrate the range of findings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      83 percent of participants in the 1986 Belfast City Marathon reported one or more GI disturbances during or immediately after running [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      81 percent of athletes competing in the 1984 Dunedin Enduro multisport (swim, bicycle, canoe, and run) event experienced GI symptoms during training [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abdominal pain (68 percent) and bowel dysfunction (49 percent) were common in triathletes during training and competitions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/5\">",
"       5",
"      </a>",
"      ]. In a prospective study, 59 percent of triathletes experienced GI symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/9\">",
"       9",
"      </a>",
"      ]. GI symptoms occurred mainly during the run portion of training and racing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single nonspecific GI complaint (45 percent) and more serious GI complaints (11 percent) were reported among 1281 long distance runners [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/10\">",
"     10",
"    </a>",
"    ]. Compared to other studies, the prevalence of GI complaints was particularly low, which may partly be due to the definition of symptoms used in the study. In most reports, GI symptoms were more common in women and in younger athletes and occurred more commonly after consumption of a meal within two to three hours of exercising [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/3,5,10-13\">",
"     3,5,10-13",
"    </a>",
"    ]. Some reports found an association with the intensity of the exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/3,5,14\">",
"     3,5,14",
"    </a>",
"    ], while no such correlation was found in others [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/11,12,15\">",
"     11,12,15",
"    </a>",
"    ]. Dehydration appears to exacerbate GI symptoms; one study demonstrated that 80 percent of marathon runners who experienced greater than 4 percent body weight loss developed GI symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a general rule, long distance runners more commonly complain of lower gastrointestinal symptoms including fecal urgency, diarrhea, and transient abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/3,5,11,13,17\">",
"     3,5,11,13,17",
"    </a>",
"    ]. Upper GI symptoms are less frequent but may include heartburn, nausea, and vomiting, as described further below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXERCISE-RELATED TRANSIENT ABDOMINAL PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-related transient abdominal pain (ETAP) is commonly referred to as a \"stitch.\" It occurs frequently during long distance running (particularly during training and racing) but also with swimming, cycling, horseback riding, and team sports [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/18\">",
"     18",
"    </a>",
"    ]. The reported incidence varies widely: 6 to 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/3-5,11,12,18,19\">",
"     3-5,11,12,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-related transient abdominal pain is often described as a side ache, side cramp, sharp or stabbing pain, cramping, aching, or pulling in the abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/18\">",
"     18",
"    </a>",
"    ]. In a representative report, ETAP was most commonly localized to the right (46 percent) and left (23 percent) middle quadrants followed by the periumbilical region (16 percent) and the right upper quadrant (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/13\">",
"     13",
"    </a>",
"    ]. It was most often characterized as aching (25 percent), sharp (22 percent), or cramping (22 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of abdominal cramping is not well understood. Several hypotheses have been proposed including diaphragmatic ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/20\">",
"     20",
"    </a>",
"    ], jolting stress on subdiaphragmatic ligaments supporting the abdominal viscera [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/21\">",
"     21",
"    </a>",
"    ], and frictional irritation of the parietal peritoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/18\">",
"     18",
"    </a>",
"    ]. Several female triathletes have described worsening symptoms with menses, suggesting that hormonal factors may also be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of ETAP includes the gradual increase in exercise conditioning and the avoidance of fatty or high caloric meals within three hours of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/12,21,22\">",
"     12,21,22",
"    </a>",
"    ]. ETAP typically resolves with the cessation of exercise or a reduction in exercise intensity. Other physical maneuvers have demonstrated some efficacy in small studies, including breathing through pursed lips after deep inhalation or bending forward while tightening abdominal muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GASTROESOPHAGEAL REFLUX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heartburn and regurgitation have been described in 10 to 17 percent of long distance runners and multisport athletes, a rate similar to that reported in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/3,4,11,13,19\">",
"     3,4,11,13,19",
"    </a>",
"    ]. Thus, the association with running is unclear. In one report, the incidence of heartburn and eructation was higher in nonrunners than in runners, and long distance runners more frequently experienced heartburn and regurgitation when not running [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, some studies report worsening of heartburn",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased reflux during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/4,5,24\">",
"     4,5,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have reported that the prevalence of gastroesophageal reflux differed among sports (higher in runners versus cyclers) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/7,21,25,26\">",
"     7,21,25,26",
"    </a>",
"    ] and the intensity of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Reflux also appears to be more common if a meal was consumed shortly before exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/21,25,26\">",
"     21,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors are believed to contribute to the development of reflux in athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/31\">",
"     31",
"    </a>",
"    ]. These include delayed gastric emptying from reduced splanchnic blood flow, impaired secretion of protective factors from the gastrointestinal mucosa, decreased esophageal clearance from a reduction in the duration, frequency, intensity of esophageal contraction, and an increase in the number of lower esophageal sphincter relaxations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/25,29,30,32,33\">",
"     25,29,30,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention and treatment of GERD in athletes consist of alterations in dietary and training regimens and possible pharmacologic management [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/31,34\">",
"     31,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One randomized, placebo-controlled study of athletes with preexisting heartburn or regurgitation found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    (20 mg per day) significantly decreased acid reflux during exercise, as measured by pH monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/35\">",
"     35",
"    </a>",
"    ]. However, omeprazole did not significantly affect exercise-induced GERD symptoms of heartburn, regurgitation, or chest pain, supporting the likelihood that the etiology of these symptoms during exercise is multifactorial.",
"   </p>",
"   <p>",
"    In patients with persistent reflux symptoms, we usually treat with acid suppression following a similar approach as for treatment of GERD in patients who are not athletes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NAUSEA AND VOMITING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea occurs in 6 to 26 percent of runners, particularly long distance runners [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/3-5,11-13,19\">",
"     3-5,11-13,19",
"    </a>",
"    ]. Vomiting is less common (2 to 6 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of exercise-induced nausea and vomiting may be similar to that of reflux in athletes, with exercise-induced delayed gastric emptying and altered intestinal motility contributing to symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/36\">",
"     36",
"    </a>",
"    ]. Although gastric acidity is not significantly altered with exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/37\">",
"     37",
"    </a>",
"    ], increases in gastric bile acid levels have been reported and may contribute to nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the likely relationship between gastric emptying and symptoms of nausea and vomiting, the avoidance of a high calorie, fatty meal three hours prior to exercising is generally recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/4,39\">",
"     4,39",
"    </a>",
"    ]. The primary treatment for nausea and vomiting associated with exercise is the prompt cessation of physical activity. However, in athletes with protracted nausea and vomiting, evaluation for complications of dehydration and electrolyte disturbances should be pursued. In addition, other causes, such as peptic ulcer disease and biliary pain, should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ACUTE DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea and the urge to defecate in long distance runners (colloquially referred to as \"runner's trots\") are common, and frequently interrupt exercise and impact performance. Exercise-associated diarrhea ranged from 14 to 38 percent in long distance runners and marathoners, while urgency to defecate during exercise ranged from 24 to 54 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/3,4,11,13,19\">",
"     3,4,11,13,19",
"    </a>",
"    ]. Fecal incontinence is relatively uncommon (4 percent).",
"   </p>",
"   <p>",
"    Athletes have described an association with the intensity of exercise, pre-race anxiety, and the proximity of the most recent meal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/3,5,13\">",
"     3,5,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of exercise-induced diarrhea remains unclear. Several etiologic factors have been suggested. Mechanical stimulation of the intestinal mucosa results in the secretion of vasoactive intestinal peptide and prostaglandins with subsequent alterations in intestinal secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Exercise-induced alterations in autonomic nervous system activity are thought to influence colonic motility [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/29\">",
"     29",
"    </a>",
"    ]. Similar studies assessing exercise-induced alterations in small bowel motility have demonstrated either delayed or unchanged motility [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. During a week of heavy training, small bowel and colonic transit were significantly accelerated in well-trained athletes compared with measurements during a week of rest. Increased stool frequency and a tendency toward looser stools were observed during the week with heavy training [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/45\">",
"     45",
"    </a>",
"    ]. Exercise also results in altered mucosal permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of prevention of exercise-induced diarrhea includes the avoidance of fatty, high caloric meals or high glycemic index foods three hours before exercising [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/39\">",
"     39",
"    </a>",
"    ]. One study suggested a benefit from an elemental diet before competitions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/48\">",
"     48",
"    </a>",
"    ]. The use of antidiarrheal medications has been suggested but should be used with caution [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/39,49\">",
"     39,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercise-induced diarrhea is typically self-limited and rarely results in dehydration or electrolyte disturbances. Reduced exercise intensity, rest, or supportive management with intravenous fluids is usually sufficient. Athletes with prolonged diarrheal symptoms or concomitant symptoms of bleeding or nausea and vomiting should be assessed for ischemic colitis, traveler's diarrhea, or other forms of infectious gastroenteritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occult bleeding has been associated with iron deficiency anemia in long distance runners [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/50\">",
"     50",
"    </a>",
"    ]. Post-race occult positive stools have been reported in 8 to 28 percent of marathon runners [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/50-55\">",
"     50-55",
"    </a>",
"    ]. The highest rate of occult positive stools (84 percent) has been described in ultramarathon runners competing in a 100 mile road race, supporting a relationship of occult bleeding with the intensity and duration of the exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anemia with low serum iron and ferritin levels has been noted, particularly in middle and long distance runners [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/50,57-61\">",
"     50,57-61",
"    </a>",
"    ]. Mean hemoglobin and hematocrit levels were lower in runners than in sex- and age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/50,57,60,61\">",
"     50,57,60,61",
"    </a>",
"    ]. While iron deficiency results in multiple physiologic effects and the influence of iron deficiency on performance in non-anemic athletes is debatable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/62\">",
"     62",
"    </a>",
"    ], identifying the etiology of the iron deficiency is important.",
"   </p>",
"   <p>",
"    Exercise-induced anemia may arise from several etiologies other than gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/63\">",
"     63",
"    </a>",
"    ]. A post-exercise dilutional pseudoanemia may occur as a result of plasma volume expansion. Intravascular mechanical hemolysis from repetitive foot-strikes or heel-strikes in long distance runners [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/64,65\">",
"     64,65",
"    </a>",
"    ] and hand-strikes in karate and other sports using repetitive hand impact have been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of exercise-induced gastrointestinal bleeding is unclear. Studies evaluating a potential association with the athlete's age, race time, abdominal symptoms, running pace, or use of nonsteroidal antiinflammatory medications have shown mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/52-54,56\">",
"     52-54,56",
"    </a>",
"    ]. Similarly, studies correlating occult bleeding with lower gastrointestinal symptoms have been inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/52,55,56\">",
"     52,55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bleeding from the stomach has been suggested in a number of reports in which endoscopy was performed in close temporal proximity to the exercise. Endoscopic findings have included hemorrhagic gastropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/68\">",
"     68",
"    </a>",
"    ], erosive gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/55\">",
"     55",
"    </a>",
"    ], gastric ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/69\">",
"     69",
"    </a>",
"    ], and ischemic colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An illustrative study evaluated 41 runners competing in the 1988 Chicago Marathon [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/55\">",
"     55",
"    </a>",
"    ]. Nine (21 percent) developed post-race fecal occult blood. Seven consented to endoscopic procedures, and three were evaluated within 48 hours. Two had bleeding antral erosions and one had hyperemia and erosions isolated to the splenic flexure on colonoscopy. In the four runners with delayed endoscopic procedures (greater than four days), no source of bleeding was found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no established methods to prevent occult bleeding in athletes, although prophylactic acid suppression with a proton pump inhibitor may be effective. However, the need for such prophylaxis is unclear, since in most cases there are usually no serious clinical sequelae.",
"   </p>",
"   <p>",
"    At least two controlled trials have evaluated the efficacy of acid reduction in reducing gastrointestinal bleeding in long distance runners [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       Cimetidine",
"      </a>",
"      (800 mg) given to participants two hours before the start of the 1990 Marine Corps Marathon and the New York City Marathon was not effective in preventing post-race fecal occult blood [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By contrast, in a study of 37 runners competing in a 246 km running event, prophylactic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"       pantoprazole",
"      </a>",
"      (20 mg) was significantly more effective than placebo in preventing fecal occult blood (10 versus 71 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possibility of occult bleeding and an evaluation for iron deficiency should be considered in any athlete with increasing complaints of fatigue or poor performance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INTESTINAL ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced intestinal ischemia is rare but has been documented in several case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. The ischemic segment most often involves the proximal colon but has also been described in the sigmoid colon and ileum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. In one report, runners presenting to an emergency department with abdominal pain, nausea, vomiting, and bleeding within 24 hours of completing the Boston Marathon were found to have variable levels of circumferential wall thickening of the cecum and other colon regions on abdominal CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/75\">",
"     75",
"    </a>",
"    ]. They also had variable involvement of the ascending, transverse, descending, and sigmoid colon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of exercise-induced intestinal ischemia is not fully understood but may be related to a decrease in mesenteric blood flow during exercise, which decreases between 50 and 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. For example, cycling for 60 minutes at 70 percent of capacity by healthy men was associated with reduced intestinal blood flow, leakage of gut-specific enzymes into plasma, and increased intestinal permeability suggesting mild injury, but no GI symptoms were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/82\">",
"     82",
"    </a>",
"    ]. In another study, splanchnic hemodynamics were measured before and after a triathlon in 59 athletes. A significant decrease in the diameter of the superior mesenteric artery (SMA), and a significant decrease in the resistive index in the SMA and celiac arteries were measured post-race using duplex Doppler ultrasound. However, these differences were similar in those athletes with and without GI symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/9\">",
"     9",
"    </a>",
"    ]. Splanchnic hypoperfusion and ischemia can be demonstrated in athletes during strenuous exercise.",
"   </p>",
"   <p>",
"    The cecum represents a vascular border zone with its blood supply arising from end arteries of the ileal or colic branches of the ileocolic artery or from an inconstant arcade that may form between the two vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/83\">",
"     83",
"    </a>",
"    ]. The predilection for right-sided ischemic colitis in athletes is thought to relate to an increased susceptibility of these end arteries in low flow states [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because intestinal ischemia is rare, no specific recommendations have been established for its prevention. In addition, the prevalence of recurrent exercise-induced ischemia is unknown. However, in patients with suspected exercise-induced ischemia, careful pre-race and race hydration should be maintained. In addition, a reduced race intensity or distance should be recommended to the athlete.",
"   </p>",
"   <p>",
"    Most patients with exercise-induced ischemic colitis have complete resolution without further management. However, several cases of exercise-induced ischemic colitis requiring surgical resection have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Such patients generally presented with hematochezia, vomiting, and progressive or severe abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;GI infections can spread rapidly among team athletes since team members are in close proximity to each other [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/84\">",
"     84",
"    </a>",
"    ]. In addition, international travel among athletes at all levels has increased dramatically in the past 20 years. Increases in numbers of athletes competing in adventure races and events involving open water swimming has led to outbreaks of infectious diseases endemic to the region of travel [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16824/abstract/85-88\">",
"     85-88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of endurance athletes experience gastrointestinal symptoms during training or races (",
"      <a class=\"graphic graphic_table graphicRef66975 \" href=\"UTD.htm?1/5/1115\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most frequent symptoms of endurance athletes are exercise-related transient abdominal pain (colloquially referred to as a \"stitch\"), heartburn and regurgitation, nausea and vomiting, and diarrhea and the urge to defecate (colloquially referred to as \"runner's trots\").",
"     </li>",
"     <li>",
"      In patients with bothersome symptoms, we suggest the avoidance of high calorie and high fat meals at least three hours before exercising (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients with persistent symptoms, we suggest a temporary decrease in exercise intensity or duration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Heartburn and regurgitation are reported in up to 17 percent of athletes but the association with exercise is not always clear. In patients with persistent reflux symptoms, we suggest pharmacologic treatment with acid suppression following a similar approach as for treatment of GERD in patients who are not athletes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"       \"Medical management of gastroesophageal reflux disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long distance running has been associated with anemia, low serum iron and ferritin levels, and occult bleeding. The most likely source of bleeding is the stomach based on limited data. There are no established methods to prevent occult bleeding in athletes, although prophylactic acid suppression with a proton pump inhibitor may be effective. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Gastrointestinal bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intestinal ischemia is frequently documented during strenuous exercise in the laboratory, but clinical ischemic bowel disease during athletic events is rare and generally resolves without treatment. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Intestinal ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Athletes who compete internationally are susceptible to a variety of infectious diseases that are endemic to the region. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Gastrointestinal infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/1\">",
"      Gil SM, Yazaki E, Evans DF. Aetiology of running-related gastrointestinal dysfunction. How far is the finishing line? Sports Med 1998; 26:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/2\">",
"      ter Steege RW, Kolkman JJ. Review article: the pathophysiology and management of gastrointestinal symptoms during physical exercise, and the role of splanchnic blood flow. Aliment Pharmacol Ther 2012; 35:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/3\">",
"      Riddoch C, Trinick T. Gastrointestinal disturbances in marathon runners. Br J Sports Med 1988; 22:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/4\">",
"      Worobetz LJ, Gerrard DF. Gastrointestinal symptoms during exercise in Enduro athletes: prevalence and speculations on the aetiology. N Z Med J 1985; 98:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/5\">",
"      Sullivan SN. Exercise-associated symptoms in triathletes. Phys Sportsmed 1987; 15:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/6\">",
"      Peters HP, De Vries WR, Vanberge-Henegouwen GP, Akkermans LM. Potential benefits and hazards of physical activity and exercise on the gastrointestinal tract. Gut 2001; 48:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/7\">",
"      Bi L, Triadafilopoulos G. Exercise and gastrointestinal function and disease: an evidence-based review of risks and benefits. Clin Gastroenterol Hepatol 2003; 1:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/8\">",
"      van Nieuwenhoven MA, Brouns F, Brummer RJ. Gastrointestinal profile of symptomatic athletes at rest and during physical exercise. Eur J Appl Physiol 2004; 91:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/9\">",
"      Wright H, Collins M, Villiers RD, Schwellnus MP. Are splanchnic hemodynamics related to the development of gastrointestinal symptoms in ironman triathletes? A prospective cohort study. Clin J Sport Med 2011; 21:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/10\">",
"      ter Steege RW, Van der Palen J, Kolkman JJ. Prevalence of gastrointestinal complaints in runners competing in a long-distance run: an internet-based observational study in 1281 subjects. Scand J Gastroenterol 2008; 43:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/11\">",
"      Keeffe EB, Lowe DK, Goss JR, Wayne R. Gastrointestinal symptoms of marathon runners. West J Med 1984; 141:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/12\">",
"      Morton DP, Richards D, Callister R. Epidemlology of exercise-related transient abdominal pain at the Sydney City to Surf community run. J Sci Med Sport 2005; 8:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/13\">",
"      Sullivan SN, Wong C, Heidenheim P. Does running cause gastrointestinal symptoms? A survey of 93 randomly selected runners compared with controls. N Z Med J 1994; 107:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/14\">",
"      Sullivan SN. The effect of running on the gastrointestinal tract. J Clin Gastroenterol 1984; 6:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/15\">",
"      Halvorsen FA, Ritland S. Gastrointestinal problems related to endurance event training. Sports Med 1992; 14:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/16\">",
"      Rehrer NJ, Janssen GM, Brouns F, Saris WH. Fluid intake and gastrointestinal problems in runners competing in a 25-km race and a marathon. Int J Sports Med 1989; 10 Suppl 1:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/17\">",
"      Peters HP, Bos M, Seebregts L, et al. Gastrointestinal symptoms in long-distance runners, cyclists, and triathletes: prevalence, medication, and etiology. Am J Gastroenterol 1999; 94:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/18\">",
"      Morton DP, Callister R. Characteristics and etiology of exercise-related transient abdominal pain. Med Sci Sports Exerc 2000; 32:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/19\">",
"      Sullivan SN. The gastrointestinal symptoms of running. N Engl J Med 1981; 304:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/20\">",
"      Capps RB. Causes of the so-called side ache in normal persons. Arch Intern Med 1941; 68:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/21\">",
"      SINCLAIR JD. Stitch: the side pain of athletes. N Z Med J 1951; 50:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/22\">",
"      Rost F. Stitch, the side pain of athletes. N Z Med J 1986; 99:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/23\">",
"      Plunkett BT, Hopkins WG. Investigation of the side pain \"stitch\" induced by running after fluid ingestion. Med Sci Sports Exerc 1999; 31:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/24\">",
"      Ravi N, Stuart RC, Byrne PJ, Reynolds JV. Effect of physical exercise on esophageal motility in patients with esophageal disease. Dis Esophagus 2005; 18:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/25\">",
"      Collings KL, Pierce Pratt F, Rodriguez-Stanley S, et al. Esophageal reflux in conditioned runners, cyclists, and weightlifters. Med Sci Sports Exerc 2003; 35:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/26\">",
"      Yazaki E, Shawdon A, Beasley I, Evans DF. The effect of different types of exercise on gastro-oesophageal reflux. Aust J Sci Med Sport 1996; 28:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/27\">",
"      Clark CS, Kraus BB, Sinclair J, Castell DO. Gastroesophageal reflux induced by exercise in healthy volunteers. JAMA 1989; 261:3599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/28\">",
"      Pandolfino JE, Bianchi LK, Lee TJ, et al. Esophagogastric junction morphology predicts susceptibility to exercise-induced reflux. Am J Gastroenterol 2004; 99:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/29\">",
"      Soffer EE, Merchant RK, Duethman G, et al. Effect of graded exercise on esophageal motility and gastroesophageal reflux in trained athletes. Dig Dis Sci 1993; 38:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/30\">",
"      Soffer EE, Wilson J, Duethman G, et al. Effect of graded exercise on esophageal motility and gastroesophageal reflux in nontrained subjects. Dig Dis Sci 1994; 39:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/31\">",
"      Parmelee-Peters K, Moeller JL. Gastroesophageal reflux in athletes. Curr Sports Med Rep 2004; 3:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/32\">",
"      Otte JA, Oostveen E, Geelkerken RH, et al. Exercise induces gastric ischemia in healthy volunteers: a tonometry study. J Appl Physiol 2001; 91:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/33\">",
"      Peters HP, Wiersma JW, Koerselman J, et al. The effect of a sports drink on gastroesophageal reflux during a run-bike-run test. Int J Sports Med 2000; 21:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/34\">",
"      Jozkow P, Wasko-Czopnik D, Medras M, Paradowski L. Gastroesophageal reflux disease and physical activity. Sports Med 2006; 36:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/35\">",
"      Peters HP, De Kort AF, Van Krevelen H, et al. The effect of omeprazole on gastro-oesophageal reflux and symptoms during strenuous exercise. Aliment Pharmacol Ther 1999; 13:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/36\">",
"      Murray R. The effects of consuming carbohydrate-electrolyte beverages on gastric emptying and fluid absorption during and following exercise. Sports Med 1987; 4:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/37\">",
"      Moses FM. The effect of exercise on the gastrointestinal tract. Sports Med 1990; 9:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/38\">",
"      Oktedalen O, Nesland A, Opstad PK, Berstad A. The influence of prolonged physical stress on gastric juice components in healthy man. Scand J Gastroenterol 1988; 23:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/39\">",
"      Butcher JD. Runner's diarrhea and other intestinal problems of athletes. Am Fam Physician 1993; 48:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/40\">",
"      Demers LM, Harrison TS, Halbert DR, Santen RJ. Effect of prolonged exercise on plasma prostaglandin levels. Prostaglandins Med 1981; 6:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/41\">",
"      Fahrenkrug J, Haglund U, Jodal M, et al. Nervous release of vasoactive intestinal polypeptide in the gastrointestinal tract of cats: possible physiological implications. J Physiol 1978; 284:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/42\">",
"      Oektedalen O, Flaten O, Opstad PK, Myren J. hPP and gastrin response to a liquid meal and oral glucose during prolonged severe exercise, caloric deficit, and sleep deprivation. Scand J Gastroenterol 1982; 17:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/43\">",
"      Ollerenshaw KJ, Norman S, Wilson CG, Hardy JG. Exercise and small intestinal transit. Nucl Med Commun 1987; 8:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/44\">",
"      Rao KA, Yazaki E, Evans DF, Carbon R. Objective evaluation of small bowel and colonic transit time using pH telemetry in athletes with gastrointestinal symptoms. Br J Sports Med 2004; 38:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/45\">",
"      Strid H, Simr&eacute;n M, St&ouml;rsrud S, et al. Effect of heavy exercise on gastrointestinal transit in endurance athletes. Scand J Gastroenterol 2011; 46:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/46\">",
"      Pals KL, Chang RT, Ryan AJ, Gisolfi CV. Effect of running intensity on intestinal permeability. J Appl Physiol 1997; 82:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/47\">",
"      Payne DL, Welsh JD, Claypool PL. Breath hydrogen (H2) response to carbohydrate malabsorption after exercise. J Lab Clin Med 1983; 102:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/48\">",
"      Bounous G, McArdle AH. Marathon runners: the intestinal handicap. Med Hypotheses 1990; 33:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/49\">",
"      Casey E, Mistry DJ, MacKnight JM. Training room management of medical conditions: sports gastroenterology. Clin Sports Med 2005; 24:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/50\">",
"      Stewart JG, Ahlquist DA, McGill DB, et al. Gastrointestinal blood loss and anemia in runners. Ann Intern Med 1984; 100:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/51\">",
"      Halvorsen FA, Lyng J, Ritland S. Gastrointestinal bleeding in marathon runners. Scand J Gastroenterol 1986; 21:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/52\">",
"      McCabe ME 3rd, Peura DA, Kadakia SC, et al. Gastrointestinal blood loss associated with running a marathon. Dig Dis Sci 1986; 31:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/53\">",
"      McMahon LF Jr, Ryan MJ, Larson D, Fisher RL. Occult gastrointestinal blood loss in marathon runners. Ann Intern Med 1984; 100:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/54\">",
"      Robertson JD, Maughan RJ, Davidson RJ. Faecal blood loss in response to exercise. Br Med J (Clin Res Ed) 1987; 295:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/55\">",
"      Schwartz AE, Vanagunas A, Kamel PL. Endoscopy to evaluate gastrointestinal bleeding in marathon runners. Ann Intern Med 1990; 113:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/56\">",
"      Baska RS, Moses FM, Graeber G, Kearney G. Gastrointestinal bleeding during an ultramarathon. Dig Dis Sci 1990; 35:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/57\">",
"      Brotherhood J, Brozovi B, Pugh LG. Haematological status of middle- and long-distance runners. Clin Sci Mol Med 1975; 48:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/58\">",
"      Dufaux B, Hoederath A, Streitberger I, et al. Serum ferritin, transferrin, haptoglobin, and iron in middle- and long-distance runners, elite rowers, and professional racing cyclists. Int J Sports Med 1981; 2:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/59\">",
"      Hunding A, Jordal R, Paulev PE. Runner's anemia and iron deficiency. Acta Med Scand 1981; 209:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/60\">",
"      Martin RP, Haskell WL, Wood PD. Blood chemistry and lipid profiles of elite distance runners. Ann N Y Acad Sci 1977; 301:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/61\">",
"      Stewart GA, Steel JE, Toyne AH, Stewart MJ. Observations on the haematology and the iron and protein intake of Australian olympic athletes. Med J Aust 1972; 2:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/62\">",
"      Peeling P, Dawson B, Goodman C, et al. Athletic induced iron deficiency: new insights into the role of inflammation, cytokines and hormones. Eur J Appl Physiol 2008; 103:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/63\">",
"      Mercer KW, Densmore JJ. Hematologic disorders in the athlete. Clin Sports Med 2005; 24:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/64\">",
"      DAVIDSON RJ. EXERTIONAL HAEMOGLOBINURIA: A REPORT ON THREE CASES WITH STUDIES ON THE HAEMOLYTIC MECHANISM. J Clin Pathol 1964; 17:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/65\">",
"      Telford RD, Sly GJ, Hahn AG, et al. Footstrike is the major cause of hemolysis during running. J Appl Physiol 2003; 94:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/66\">",
"      C&oacute;rdova Mart&iacute;nez A, Villa G, Aguil&oacute; A, et al. Hand strike-induced hemolysis and adaptations in iron metabolism in Basque ball players. Ann Nutr Metab 2006; 50:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/67\">",
"      Streeton JA. Traumatic haemogloinuria caused by karate exercises. Lancet 1967; 2:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/68\">",
"      Papaioannides D, Giotis C, Karagiannis N, Voudouris C. Acute upper gastrointestinal hemorrhage in long-distance runners. Ann Intern Med 1984; 101:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/69\">",
"      Rubin RB, Saltzman JR, Zawacki JK. Bicycle racing, Raynaud's phenomenon, and gastrointestinal bleeding. Am J Gastroenterol 1994; 89:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/70\">",
"      Heer M, Repond F, Hany A, et al. Acute ischaemic colitis in a female long distance runner. Gut 1987; 28:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/71\">",
"      Moses FM, Baska RS, Peura DA, Deuster PA. Effect of cimetidine on marathon-associated gastrointestinal symptoms and bleeding. Dig Dis Sci 1991; 36:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/72\">",
"      Thalmann M, Sodeck GH, Kavouras S, et al. Proton pump inhibition prevents gastrointestinal bleeding in ultramarathon runners: a randomised, double blinded, placebo controlled study. Br J Sports Med 2006; 40:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/73\">",
"      Beaumont AC, Teare JP. Subtotal colectomy following marathon running in a female patient. J R Soc Med 1991; 84:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/74\">",
"      Kam LW, Pease WE, Thompson PD. Exercise-related mesenteric infarction. Am J Gastroenterol 1994; 89:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/75\">",
"      Kyriakos R, Siewert B, Kato E, et al. CT findings in runner's colitis. Abdom Imaging 2006; 31:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/76\">",
"      Lucas W, Schroy PC 3rd. Reversible ischemic colitis in a high endurance athlete. Am J Gastroenterol 1998; 93:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/77\">",
"      Moses FM. Exercise-associated intestinal ischemia. Curr Sports Med Rep 2005; 4:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/78\">",
"      Moses FM, Brewer TG, Peura DA. Running-associated proximal hemorrhagic colitis. Ann Intern Med 1988; 108:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/79\">",
"      Clausen JP. Effect of physical training on cardiovascular adjustments to exercise in man. Physiol Rev 1977; 57:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/80\">",
"      Rowell LB. Human cardiovascular adjustments to exercise and thermal stress. Physiol Rev 1974; 54:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/81\">",
"      ter Steege RW, Geelkerken RH, Huisman AB, Kolkman JJ. Abdominal symptoms during physical exercise and the role of gastrointestinal ischaemia: a study in 12 symptomatic athletes. Br J Sports Med 2012; 46:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/82\">",
"      van Wijck K, Lenaerts K, van Loon LJ, et al. Exercise-induced splanchnic hypoperfusion results in gut dysfunction in healthy men. PLoS One 2011; 6:e22366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/83\">",
"      Rist CB, Watts JC, Lucas RJ. Isolated ischemic necrosis of the cecum in patients with chronic heart disease. Dis Colon Rectum 1984; 27:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/84\">",
"      Kilgore PE, Belay ED, Hamlin DM, et al. A university outbreak of gastroenteritis due to a small round-structured virus. Application of molecular diagnostics to identify the etiologic agent and patterns of transmission. J Infect Dis 1996; 173:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/85\">",
"      Leptospirosis outbreak in Eco Challenge 2000 participants. Commun Dis Rep CDR Wkly 2000; 10:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/86\">",
"      Haddock RL, Gilmore JW, Pimentel F. A leptospirosis outbreak on Guam associated with an athletic event. Pac Health Dialog 2002; 9:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/87\">",
"      Morgan J, Bornstein SL, Karpati AM, et al. Outbreak of leptospirosis among triathlon participants and community residents in Springfield, Illinois, 1998. Clin Infect Dis 2002; 34:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16824/abstract/88\">",
"      Sejvar J, Bancroft E, Winthrop K, et al. Leptospirosis in \"Eco-Challenge\" athletes, Malaysian Borneo, 2000. Emerg Infect Dis 2003; 9:702.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2623 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16824=[""].join("\n");
var outline_f16_27_16824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXERCISE-RELATED TRANSIENT ABDOMINAL PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GASTROESOPHAGEAL REFLUX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NAUSEA AND VOMITING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ACUTE DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GASTROINTESTINAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INTESTINAL ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      GASTROINTESTINAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2623\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2623|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/5/1115\" title=\"table 1\">",
"      GI Sx disease in athletes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_27_16825="Pathophysiology and clinical features of atrial septal defects in adults";
var content_f16_27_16825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and clinical features of atrial septal defects in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16825/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16825/contributors\">",
"     Martin G St. John Sutton, MBBS, FRCP, FACC, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16825/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16825/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16825/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16825/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16825/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/27/16825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial septal defect (ASD) is the most common congenital heart lesion in adults after bicuspid aortic valve. Although the defect is often asymptomatic until adulthood, potential complications of an undetected ASD include right ventricular failure, atrial arrhythmias, paradoxical embolization, cerebral abscess, and pulmonary hypertension that can become irreversible and lead to right-to-left shunting (Eisenmenger syndrome).",
"   </p>",
"   <p>",
"    The pathophysiology, anatomy, natural history, and clinical features of ASDs in adults will be reviewed here. The identification and assessment of ASDs, methods for treatment, and issues related to ASDs in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5896?source=see_link\">",
"     \"Identification and assessment of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link\">",
"     \"Management of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=see_link\">",
"     \"Management and outcome of isolated atrial septal defects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated communications in the atrial septum have several distinctive anatomic locations. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Embryology'",
"    </a>",
"    below.) However, the pathophysiology of each lesion is similar. With a small ASD, left atrial pressure is slightly higher than right atrial pressure, resulting in the flow of oxygenated blood from the left to the right atrium across the defect (",
"    <a class=\"graphic graphic_figure graphicRef72533 \" href=\"UTD.htm?23/17/23826\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef80448 \" href=\"UTD.htm?6/56/7040\">",
"     movie 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The pressure gradient between the two atria and the amount of shunt flow depend upon the size of the defect, and the relative distensibility of the right and left sides of the heart. Left-to-right shunting occurs primarily in late ventricular systole and early diastole, with some augmentation during atrial systole. Even when the right and left atrial pressures are equal, as occurs with a large defect, left-to-right shunting still occurs because of the greater compliance of the right compared to left ventricle.",
"   </p>",
"   <p>",
"    However, shunting varies during the phases of the cardiac cycle&nbsp;and transient intra-cardiac right-to-left shunting in virtually all patients coincides with the onset of ventricular contraction, particularly under conditions&nbsp;of bradycardia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased intrathoracic pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/1\">",
"     1",
"    </a>",
"    ]. This explains the possibility for right-to-left shunting&nbsp;and neurologic events in patients who are not cyanotic.",
"   </p>",
"   <p>",
"    The shunt flow constitutes a \"useless circuit\" through the right atrium, right ventricle, pulmonary circulation, left atrium, and through the defect back to the right atrium. The pulmonary flow to systemic flow ratio can be as high as 8:1 but, in asymptomatic young adults, is more likely to be in the range of 2:1 to 5:1. The increased flow leads to right-sided dilatation evident on chest x-ray and echocardiographic imaging. The main pulmonary arteries dilate and the pulmonary vascularity increases. These changes may be evident on the chest x-ray, and large vessels in both the lower and upper lobes may be seen.",
"   </p>",
"   <p>",
"    The right-sided volume overload is usually well tolerated for years. In select patients, development of pulmonary arteriopathy signals the onset of progressive pulmonary hypertension and its sequel tricuspid regurgitation, Eisenmenger syndrome with right ventricular failure and right-to-left shunting of blood. The development of pulmonary hypertension is highly variable and depends not only on the size and duration of the shunt but on several unknown individual factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"     \"Evaluation and prognosis of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial septation begins as early as the fifth week of gestation. The septum primum arises from the superior portion of the common atrium and grows caudally to the endocardial cushions located between the atria and ventricles, eventually closing the orifice (ostium primum) between the atria (",
"    <a class=\"graphic graphic_figure graphicRef77749 \" href=\"UTD.htm?2/6/2153\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A second orifice (the ostium secundum) develops in the septum primum; this orifice is covered by another septum (the septum secundum) that arises on the right atrial side of the septum primum. The septum secundum grows caudally and covers the ostium secundum. However, the septum secundum does not completely divide the atria, but leaves an oval orifice (the foramen ovale) that is covered but not sealed on the left side by the flexible flap of the septum primum (",
"    <a class=\"graphic graphic_figure graphicRef77749 \" href=\"UTD.htm?2/6/2153\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the fetus, the foramen ovale is held open by the pressure gradient between the right and left atria; the right atrial pressure is higher than that on the left and pushes the flexible septum primum aside. At birth, expansion of the lungs lowers right heart pressures at the same time that systemic vascular resistance rises, causing reversal of the atrial gradient. The septum primum is then held against the septum secundum and the interatrial shunt ceases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link&amp;anchor=H12#H12\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\", section on 'Perinatal physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In approximately 70 percent of individuals, the primum and secundum septa fuse after birth creating an intact interatrial septum. However, in a significant proportion of the population, the septa do not fuse. If the foramen ovale is completely covered but not sealed, it is called a \"probe patent\" or simply \"patent\" foramen ovale (PFO), indicating that the foramen can be opened by a reversal of the interatrial pressure gradient or by an intracardiac catheter. Less commonly, an open communication persists between the atria after septation. Such a communication is called an atrial septal defect (ASD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various types of ASDs are classified according to their location and the nature of the embryologic defect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated ASDs result from abnormal development of the septa that partition the common atrium of the developing heart into right and left chambers.",
"     </li>",
"     <li>",
"      Atrioventricular (AV) septal defects (AVSD, also known as atrio-ventricular canal or endocardial cushion defects) result primarily from maldevelopment of the partitioning of the AV canal by the endocardial cushions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isolated ASDs include PFO, ASD at the fossa ovalis (secundum ASD), a defect superior to the fossa ovalis (superior sinus venosus type ASD, superior vena caval defect), a defect inferior to the fossa ovalis (inferior sinus venosus type ASD, inferior vena caval defect), and coronary sinus defects (",
"    <a class=\"graphic graphic_figure graphicRef52106 \" href=\"UTD.htm?7/36/7748\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Atrioventricular septal defects are by definition not isolated and include complete forms, incomplete forms, and common atrium. Primum ASDs are a type of AVSD and are typically associated with abnormalities of the AV valves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Secundum ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in the foramen ovalis are classified as secundum type ASD. This type of ASD can result from poor growth of the secundum septum or excessive absorption of the primum septum (",
"    <a class=\"graphic graphic_figure graphicRef52106 \" href=\"UTD.htm?7/36/7748\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef79348 \" href=\"UTD.htm?22/39/23167\">",
"     movie 2",
"    </a>",
"    ). This defect accounts for 70 to 75 percent of all ASDs and is more common in females. Secundum ASDs may be associated with or continuous with other ASDs, such as a sinus venosus defect or an ostium primum defect.",
"   </p>",
"   <p>",
"    Mitral valve prolapse is present in up to 70 percent of patients with secundum ASD, perhaps related to a change in the left ventricular geometry associated with right ventricular volume overload. The rare combination of an ASD with mitral stenosis, the result of rheumatic valvulitis, is known as Lutembacher syndrome.",
"   </p>",
"   <p>",
"    Although most cases of secundum ASD are isolated, some individuals have a family history of this defect with or without other congenital cardiac and extracardiac abnormalities. These syndromes typically present in childhood or adolescence and are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link&amp;anchor=H5#H5\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\", section on 'Genetic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely patients with a secundum ASD have a partial anomalous pulmonary venous connection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primum ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primum type ASD develops if the primum septum does not fuse with the endocardial cushions, leaving a defect at the base of the interatrial septum that is usually large (",
"    <a class=\"graphic graphic_figure graphicRef52106 \" href=\"UTD.htm?7/36/7748\">",
"     figure 3",
"    </a>",
"    ). This type of defect accounts for 15 to 20 percent of ASDs. It has been suggested that both partial and complete AV canal defects are related to maldevelopment of the ventricular septum rather than a decrease in atrial septal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primum ASDs are generally not isolated and are nearly always associated with anomalies of the AV valves, particularly a cleft in the anterior mitral valve leaflet,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    defects of the ventricular septum (called a complete endocardial cushion defect) or common AV canal that are more common in trisomy 21. Discrete sub-aortic stenosis may develop following primum ASD repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sinus venosus ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus venosus defects account for five to ten percent of ASDs. These defects represent an abnormality in the insertion of the superior or inferior vena cava, which overrides the interatrial septum; the interatrial communication is then formed within the mouth of the overriding vein and is outside the area of the fossa ovalis (",
"    <a class=\"graphic graphic_figure graphicRef52106 \" href=\"UTD.htm?7/36/7748\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/3\">",
"     3",
"    </a>",
"    ]. A partial anomalous pulmonary venous connection is present in most patients (eg, 112 of 115 patients undergoing surgical repair) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sinus venosus ASDs are of two types [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superior sinus venosus defects (sometimes called superior vena caval defects) are located in the atrial septum immediately below the orifice of the superior vena cava. The right upper lobe and middle lobe pulmonary veins often connect to the junction of the superior vena cava and right atrium, resulting in a partial anomalous pulmonary venous connection [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inferior sinus venosus defects, also known as inferior vena caval defects, are less common. They are located in the atrial septum immediately above the orifice of the inferior vena cava. These defects are also often associated with partial anomalous connection of the right pulmonary veins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even if the pulmonary veins are in their usual anatomic location, either of the right pulmonary veins may have its flow directed into the right atrium, depending upon the location of the venosus defect. The pulmonary veins may also be completely displaced and insert into either vena cava. The \"scimitar sign\" describes the opacity on the chest x-ray formed by the insertion of the pulmonary vein into the inferior vena cava. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Chest x-ray'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The triad of partial anomalous pulmonary venous return, hypoplasia or aplasia of a lobe of the right lung (most often), and the presence of thoracic aorta to pulmonary artery collaterals to the small lung is referred to as the \"scimitar syndrome.\" This syndrome may be associated with the development of pulmonary hypertension.",
"   </p>",
"   <p>",
"    The hemodynamic effect of partial anomalous venous return depends upon the number of malplaced pulmonary veins and the proportion of right ventricular stroke volume that perfuses the lung drained by these veins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coronary sinus ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In coronary sinus ASDs, part or all of the common wall between the coronary sinus and the left atrium is absent. This defect accounts for less than 1 percent of ASDs. Many such patients also have a persistent left superior vena cava.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patent foramen ovale",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patent foramen ovale (PFO), which can be detected in approximately 25 to 30 percent of normal adult hearts, is another form of interatrial communication associated with shunting of blood. This lesion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=see_link\">",
"     \"Patent foramen ovale\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of ASDs has primarily been documented in reports prior to the age of enhanced diagnosis by echocardiography. Selection bias may have been present in these studies since it was the symptomatic patients who were brought to medical attention.",
"   </p>",
"   <p>",
"    Most children and adolescents with an ASD, particularly an isolated secundum ASD, are asymptomatic even in the presence of large shunts. This was illustrated in a review of 481 patients with a secundum ASD seen between 1957 and 1976 who underwent surgical correction before the age of 40; the defect was discovered on routine examination in 202 (42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/6\">",
"     6",
"    </a>",
"    ]. In comparison, patients who present in infancy, particularly with heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    failure to thrive, usually have associated cardiac defects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link&amp;anchor=H16#H16\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\", section on 'Presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies in which serial echocardiographic examinations were performed have shown that, among newborns with an ASD, the majority of defects close spontaneously in infancy, with the exception of those larger than 8 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/8\">",
"     8",
"    </a>",
"    ]. In comparison, spontaneous closure is uncommon in children, since most ASDs that will close spontaneously will have already done so.",
"   </p>",
"   <p>",
"    The natural history of secundum ASDs in children was illustrated in a series of 104 patients (average age 4.5 years at diagnosis) who had an isolated ASD &gt;3 mm in size; serial echocardiograms were performed at an interval of more than six months between studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/9\">",
"     9",
"    </a>",
"    ]. Spontaneous closure of the ASD occurred in only four patients, while ASD diameter increased in 65 percent; 30 percent of patients had a &gt;50 percent increase in diameter and 12 percent had an increase to &gt;20 mm. The only independent factor associated with growth was the initial size of the ASD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=see_link&amp;anchor=H2#H2\">",
"     \"Management and outcome of isolated atrial septal defects in children\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in left-to-right shunting with age in many patients with uncorrected moderate to large ASDs increases the likelihood of developing symptoms as described in the next section. The increase in ASD size over time also has important implications for treatment, since there is the potential that ASD enlargement will be sufficient to preclude the use of percutaneous transcatheter closure with specific devices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of atrial septal defects in adults\", section on 'Percutaneous closure of secundum ASDs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that most patients with an ASD with significant shunt flow (ie, pulmonary to systemic flow more than 2:1) will be symptomatic and require surgical correction by the age of 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/6\">",
"     6",
"    </a>",
"    ]. However, some patients do not become symptomatic until 60 years of age or older [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Patients with unexplained right ventricular volume overload should be referred for evaluation of possible obscure ASD, partial anomalous venous connection, or coronary sinus ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial symptoms associated with an ASD may be mild and ignored by the patient. As an example, in one series of 32 patients diagnosed by incidental findings on physical examination, chest x-ray, or echocardiography who were thought to be asymptomatic, exercise tolerance improved after closure of the ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrial arrhythmias, exercise intolerance, fatigue, dyspnea, and overt heart failure are common manifestations of symptomatic ASDs. In the series cited above of 481 patients with a secundum ASD who were seen between 1957 and 1976 and who underwent surgery before the age of 40, more than one-half had symptoms of dyspnea and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Atrial arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial arrhythmias are a common manifestation of an ASD. In three series with a total of over 600 patients, atrial fibrillation or atrial flutter was present in almost 20 percent overall [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/11,14,15\">",
"     11,14,15",
"    </a>",
"    ]. The risk of atrial arrhythmias increases with age and pulmonary artery pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In a report of 211 adults, the incidence of atrial fibrillation or atrial flutter prior to surgery was 1 percent for those aged 18 to 40, 30 percent for those aged 40 to 60, and 80 percent in those over the age of 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/14\">",
"     14",
"    </a>",
"    ]. The effect of surgical repair on these arrhythmias is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of atrial septal defects in adults\", section on 'Atrial tachyarrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with atrial fibrillation are at risk for embolic events, particularly if not appropriately anticoagulated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular failure is uncommon, but can occur after many years in patients with an uncomplicated ASD. More subtle evidence of left ventricular dysfunction is a frequent finding. In a report of 12 adults with a secundum ASD, the mean cardiac index was significantly reduced compared to an age-matched group of normal subjects (3.6 versus 4.5",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    per m2) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of this complication is unclear since the primary pathophysiologic change is right ventricular volume overload. Early studies suggested an associated intrinsic left ventricular abnormality. However, it is currently thought that reversible mechanical factors operating primarily on diastolic function are of primary importance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/17\">",
"     17",
"    </a>",
"    ]. In an echocardiographic study of 34 children (mean age 9 years) undergoing percutaneous device closure of an ASD, left ventricular end-diastolic volume (LVEDV) was diminished prior to the procedure as a result of leftward interventricular septal shift [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/18\">",
"     18",
"    </a>",
"    ]. After ASD closure, LVEDV increased significantly (from 56.4 to 65.3 ml) as septal shift resolved, with a resulting increase in ejection fraction (from 54.9 to 62.1 percent).",
"   </p>",
"   <p>",
"    Systemic hypertension, if present, can exacerbate the hemodynamic changes due to an ASD. The development of left ventricular hypertrophy is associated with an increase in left ventricular stiffness. These changes tend to increase in left-to-right shunting, possibly resulting in the late development of pulmonary hypertension and right-sided heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Stroke due to paradoxical embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a PFO or, much less often, an ASD with a right-to-left shunt are at risk for stroke due to paradoxical embolization (stroke, transient ischemic attack, or peripheral emboli) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Migraine headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence is conflicting whether migraine is associated with right to left shunt via PFO or ASD. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H130649662#H130649662\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Right-to-left cardiac shunt'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H27#H27\">",
"     \"Preventive treatment of migraine in adults\", section on 'Closure of right-to-left cardiac shunt'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension and Eisenmenger syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal pulmonary vasculature accommodates the increased volume of flow in patients with an ASD by recruitment of previously under-perfused vessels. As a result, pulmonary artery pressures do not rise significantly unless the volume of pulmonary blood flow exceeds 2.5 times baseline. The development of pulmonary vascular injury is related to the degree and duration of right heart volume overload. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis of pulmonary hypertension\", section on 'Congenital heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Moderate to severe pulmonary hypertension is relatively uncommon in patients with an ASD, being present in less than 10 percent of adults at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/11,24\">",
"     11,24",
"    </a>",
"    ]. Patients with a sinus venosus defect have higher pulmonary artery pressures and resistances and develop pulmonary hypertension at an earlier age compared to patients with other forms of ASD. In a study of 169 patients, for example, pulmonary hypertension was present in 26 percent of those with a sinus venosus defect compared to 9 percent with an isolated secundum ASD; elevated pulmonary vascular resistance was present in 16 and 4 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of severe irreversible pulmonary hypertension or Eisenmenger syndrome (irreversible pulmonary hypertension at near systemic levels and reversal of shunt flow to a predominantly right-to-left direction) is now uncommon because of surgical or percutaneous correction of the defect. However, there may be an appreciable lifetime incidence of severe pulmonary hypertension in unoperated ASDs, with some older estimates being in the range of 50 percent. Although Eisenmenger syndrome is much less common with ASDs than with ventricular septal defects, ASDs have been a common cause of the syndrome because of their greater prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/26\">",
"     26",
"    </a>",
"    ]. The prognosis is relatively poor once Eisenmenger physiology has been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"     \"Evaluation and prognosis of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of pulmonary hypertension and the efficacy of repair of the ASD were evaluated in a report of 179 consecutive adults over the age of 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/11\">",
"     11",
"    </a>",
"    ]. Among these patients, 26 percent had mild to moderate pulmonary hypertension (pulmonary artery systolic pressure 40 to 60 mmHg), 7 percent had severe pulmonary hypertension (pulmonary artery systolic pressure greater than 60 mmHg), and 2 percent had a marked elevation in pulmonary vascular resistance indicative of severe pulmonary vascular obstructive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/11\">",
"     11",
"    </a>",
"    ]. The patients who underwent surgical repair (at a mean age of 56 years) had a higher adjusted 10-year survival when compared to those treated medically (95 versus 84 percent) and a much lower rate of functional deterioration (relative risk 0.21). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link\">",
"     \"Management of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cyanosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanosis in patients with ASD is usually associated with Eisenmenger syndrome in which there is shunting of unoxygenated blood from the right to the left atrium. (",
"    <a class=\"graphic graphic_picture graphicRef77116 \" href=\"UTD.htm?33/23/34174\">",
"     picture 1",
"    </a>",
"    ) (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"     \"Evaluation and prognosis of Eisenmenger syndrome\"",
"    </a>",
"    .) In addition, transient reversal of the atrial pressure gradient and transient cyanosis can be induced by some respiratory maneuvers, such as forceful crying, Valsalva, and cough.",
"   </p>",
"   <p>",
"    In rare instances, right-to-left shunting across the ASD can lead to cyanosis without pulmonary hypertension being present. In these cases, some unusual anatomic feature is responsible for directing unoxygenated blood across the defect to the left atrium in the absence of a reversed pressure gradient. Examples include prominent Eustachian valves, associated severe tricuspid valve regurgitation, right atrial masses, and distortion of the usual anatomy by a dilated coronary sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Orthodeoxia-platypnea syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=see_link&amp;anchor=H13#H13\">",
"     \"Patent foramen ovale\", section on 'Platypnea-orthodeoxia syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues relating to pregnancy in women with ASDs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link&amp;anchor=H33#H33\">",
"     \"Management of atrial septal defects in adults\", section on 'Pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link&amp;anchor=H19741008#H19741008\">",
"     \"Management of atrial septal defects in adults\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Scuba diving and altitude exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with small ASDs who are treated medically may be at increased risk for complications when they experience high or low atmospheric pressure as with scuba diving or high-altitude climbing. Scuba diving in patients with an ASD or a PFO has been associated with increased risks of decompression illness and paradoxical emboli, while high-altitude exposure has been associated with risk of increased right-to-left shunting and oxygen desaturation. Among patients with an ASD (or other intracardiac shunt), scuba diving is generally contraindicated, while consultation with a cardiologist specializing in congenital defects is recommended before altitude exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link\">",
"     \"Complications of scuba diving\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link&amp;anchor=H15#H15\">",
"     \"High altitude, air travel, and heart disease\", section on 'Congenital heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic physical findings of an ASD are related to the size and location of the defect, the size of the shunt at atrial level, and the pulmonary arterial pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Precordial palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilatation of the right atrium and right ventricle may initially be undetectable on physical examination. Eventually, large left-to-right shunts can lead to one or more of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An enlarged and hyperdynamic right ventricle can produce a right ventricular heave that is most pronounced along the left sternal border and in the subxiphoid area. It can also cause chest wall deformity with asymmetry and a left precordial bulge.",
"     </li>",
"     <li>",
"      Enlargement of the pulmonary artery may be associated with a palpable pulmonary artery impulse at the left upper sternal border. This may be more pronounced in patients with pulmonary hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Heart sounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic finding in ASDs with large left-to-right shunts and normal pulmonary artery pressure is wide, fixed splitting of the second heart sound (S2), in contrast to the normal variation in splitting during the respiratory cycle. The second sound should be evaluated when the patient is sitting or standing because splitting may be relatively wide but not fixed in the supine position. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fixed splitting is thought to result from altered characteristics of the pulmonary vascular bed associated with increased pulmonary blood flow. In all individuals, the aortic and pulmonic closure sounds (A2 and P2) occur shortly after (but not instantly after) ventricular pressure falls below arterial pressure. The delay between the ventricular pressure drop and valve closure is referred to as the \"hangout time,\" and is the delay due to pressure recoil from the arterial bed.",
"   </p>",
"   <p>",
"    In the systemic arterial circulation, the hangout time is short because of high aortic impedance and rapid pressure recoil; it does not vary with respiration. In contrast, the pulmonary hangout time is longer, because of the greater compliance of the pulmonary vascular bed, and is prolonged by inspiration, which increases pulmonary capacitance. As a result, P2 normally occurs after A2, and this separation (\"splitting\") of S2 increases with inspiration.",
"   </p>",
"   <p>",
"    With an ASD, the capacitance of the pulmonary bed is increased throughout the respiratory cycle without much respiratory variation. The increased and constant capacitance results in an increased and fixed hangout time, with wide splitting between the first and second components of the S2 and little respiratory variation.",
"   </p>",
"   <p>",
"    The intensities of the pulmonic and aortic components of S2 are equal in most patients with an uncomplicated ASD. Patients with pulmonary hypertension usually have an accentuated pulmonic component of S2. A similar finding is occasionally seen with normal pulmonary pressures, because of the proximity of the dilated pulmonary artery to the chest wall.",
"   </p>",
"   <p>",
"    The first heart sound (S1), which is heard best at the apex and lower left sternal border, is often split and the second component (tricuspid closure) is intensified in patients with an ASD. An explanation for this increase in intensity is that the large volume of diastolic blood flow from right atrium to right ventricle presses the tricuspid leaflets toward the right ventricular wall and the forceful right ventricular contraction causes the tricuspid leaflets to move abruptly cephalad during systole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Heart murmurs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shunt flow across the ASD has too low a velocity and produces too little turbulence to be audible, although it can be demonstrated by intracardiac phonocardiography. However, several other murmurs may be heard. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A midsystolic pulmonary flow or ejection murmur, resulting from the increased blood flow across the pulmonic valve, is classically present with moderate to large left-to-right shunts. This murmur is loudest over the second left intercostal space and is usually not associated with a thrill. The presence of a thrill typically indicates a very large shunt or pulmonic stenosis.",
"     </li>",
"     <li>",
"      A murmur of mitral regurgitation may also be heard due to a cleft mitral valve in ostium primum defects and mitral valve prolapse in secundum defects. In the latter setting, an apical late or holosystolic murmur of mitral regurgitation radiating to the axilla may be heard.",
"     </li>",
"     <li>",
"      A diastolic rumble due to the increased flow across the tricuspid valve may be heard by a careful examiner but is usually quite subtle. The rumble is accentuated by inspiration.",
"     </li>",
"     <li>",
"      A low-pitched diastolic murmur of pulmonic regurgitation may result from dilatation of the pulmonary artery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right-to-left shunting due to pulmonary hypertension in the occasional patient with ASD may be associated with the following auscultatory findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A right ventricular fourth heart sound",
"     </li>",
"     <li>",
"      A mid-systolic ejection click",
"     </li>",
"     <li>",
"      A mid-systolic pulmonic murmur that is softer and shorter because the ejected stroke volume is less",
"     </li>",
"     <li>",
"      No tricuspid flow murmur",
"     </li>",
"     <li>",
"      Increased intensity of the pulmonic component of S2, but no fixed splitting",
"     </li>",
"     <li>",
"      A pulmonic insufficiency murmur, if present, is high-pitched",
"     </li>",
"     <li>",
"      A holosystolic murmur of tricuspid insufficiency may result from right ventricular and atrial enlargement",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Eisenmenger syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of Eisenmenger physiology is accompanied by signs of right ventricular failure (including elevated jugular venous pressure, hepatic congestion, and pedal edema), cyanosis, and clubbing, in addition to the auscultatory features of pulmonary hypertension described above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"     \"Evaluation and prognosis of Eisenmenger syndrome\"",
"    </a>",
"    .) As the disease progresses, features of right ventricular failure (including elevated jugular venous pressure, hepatic congestion, tricuspid regurgitation, and pedal edema) are noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ELECTROCARDIOGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) may be normal with an uncomplicated ASD and small shunt. Most affected individuals have normal sinus rhythm, but atrial arrhythmias often occur beyond the third decade (especially atrial fibrillation but also atrial flutter and supraventricular tachycardia).",
"   </p>",
"   <p>",
"    P waves are typically normal with secundum ASDs. In comparison, sinus venosus ASDs are often associated with a leftward frontal plane P-wave axis (ie, negative in leads III and aVF and positive in lead aVL) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/28\">",
"     28",
"    </a>",
"    ]. This leftward shift is caused by an ectopic pacemaker resulting from an ASD located near the sinus node.",
"   </p>",
"   <p>",
"    First degree AV block can occur in any type of ASD, but is classically present in ostium primum defects in association with complete right bundle branch block and left anterior fascicular block. The rim of the ostium primum defect is in close spatial relationship to the His bundle accounting for abnormalities of impulse conduction through this area.",
"   </p>",
"   <p>",
"    The frontal plane QRS axis often ranges from +95&ordm; to +135&ordm; (right axis deviation) with a clockwise loop. Left axis deviation of the QRS axis with a counterclockwise frontal plane loop can occur with uncomplicated secundum ASD, although it usually suggests the presence of an AV canal defect.",
"   </p>",
"   <p>",
"    The QRS complex is often slightly prolonged and has a characteristic rSr' or rsR' pattern that is thought to result from disproportionate thickening of the right ventricular outflow tract, which is the last portion of the ventricle to depolarize. This pattern, which is often described as incomplete right bundle branch block, results from hypertrophy rather than a conduction disturbance. Patients with increasing pulmonary hypertension tend to lose the rSr' pattern in V1 and develop a tall monophasic R wave with a deeply inverted T wave.",
"   </p>",
"   <p>",
"    A notch on the R wave in the inferior leads (a pattern called \"crochetage\") has also been suggested as a sensitive and specific electrocardiographic sign of ASD. In one report, this finding was present in 73 percent of patients with ASD versus 7.4 percent of normals, 36 percent of ventricular septal defects, and 23 percent of patients with pulmonic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/29\">",
"     29",
"    </a>",
"    ]. In patients with ASD, it correlates with the size of the defect and the degree of left-to-right shunt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     CHEST X-RAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph reflects the dilatation of the right atrium, ventricle, and pulmonary arteries. Left atrial enlargement may be seen if there is associated mitral regurgitation. Shunt vascularity is characterized by enlarged main pulmonary arteries and pulmonary vessels, without redistribution of flow to the apical vessels (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64946 \" href=\"UTD.htm?28/5/28755\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In comparison to these classic findings, the radiographic appearance in patients diagnosed at a later age may be atypical. The atypical findings include normal vasculature, evidence of pulmonary venous hypertension, left atrial enlargement, and pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/30\">",
"     30",
"    </a>",
"    ]. In one study, atypical findings were more common in patients over the age of 50 (30 versus 6 percent in younger subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with a sinus venosus defect, the insertion of the pulmonary vein into the inferior vena cava can be seen as an abnormal density on the chest x-ray called the \"scimitar sign\" [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/31\">",
"     31",
"    </a>",
"    ]. The scimitar sign is a vertical, gently curved, right-sided paracardiac linear density that increases in width as it approaches the right cardiophrenic angle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the investigation of choice for the diagnosis of ASD. Transthoracic echocardiography (TTE) is usually definitive in ostium secundum defects, while trans-esophageal echocardiography (TEE) may aid in sizing of defects, the diagnosis of sinus venosus defects, and the assessment of associated congenital anomalies or other abnormalities such as mitral valve prolapse and anomalous pulmonary venous return. Shunt volume, shunt ratios, and pulmonary artery pressures can be measured with Doppler flow echocardiography. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5896?source=see_link\">",
"     \"Identification and assessment of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2556994\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An ASD is an open communication between the atria via a defect in the interatrial septum. A patent foramen ovale is a foramen that is covered by the septum primum but is not sealed shut in approximately 20 percent of normal subjects. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Embryology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pressure gradient between the two atria and the amount of shunt flow depend upon the size of the ASD, and the relative distensibility of the right and left sides of the heart. With a small ASD, left atrial pressure is slightly higher than right atrial pressure, resulting in the flow of oxygenated blood from the left to the right atrium across the defect (",
"      <a class=\"graphic graphic_figure graphicRef72533 \" href=\"UTD.htm?23/17/23826\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef80448 \" href=\"UTD.htm?6/56/7040\">",
"       movie 1",
"      </a>",
"      ). Even when the right and left atrial pressures are equal, as occurs with a large defect, left-to-right shunting still occurs because of the greater compliance of the right compared to left ventricle. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shunting across an ASD varies during the phases of cardiac cycle&nbsp;and transient intracardiac right-to-left shunting coincides with the onset of ventricular contraction in virtually all patients, particularly under conditions&nbsp;of bradycardia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decreased intrathoracic pressure. This explains the possibility of right-to-left shunting&nbsp;and neurologic events in patients who are not cyanotic.",
"     </li>",
"     <li>",
"      The right-sided volume overload from an ASD is usually well tolerated for years. The development of pulmonary hypertension is highly variable and depends not only on the size and duration of the shunt but on unknown individual factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Pulmonary hypertension and Eisenmenger syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"       \"Evaluation and prognosis of Eisenmenger syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ASD types include ASD at the fossa ovalis (secundum ASD), a defect superior to the fossa ovalis (superior sinus venosus type ASD, superior vena caval defect), a defect inferior to the fossa ovalis (inferior sinus venosus type ASD, inferior vena caval defect), and coronary sinus defects (",
"      <a class=\"graphic graphic_figure graphicRef52106 \" href=\"UTD.htm?7/36/7748\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atrio-ventricular septal defects include complete forms, incomplete forms, and common atrium (atrial communis). Primum ASDs are a type of AVSD and are typically associated with ventricular septal defects",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      AV valve malformations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with an ASD with significant shunt flow (ie, pulmonary to systemic flow more than 2:1) will be symptomatic (with atrial arrhythmias, exercise intolerance, fatigue, dyspnea, and heart failure) and require surgical correction by the age of 40. However, some patients do not become symptomatic until 60 years of age or older. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with unexplained right ventricular volume overload should be referred for evaluation of possible obscure ASD, partial anomalous venous connection, or coronary sinoseptal defect. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with an ASD (or other intracardiac shunt), scuba diving is generally contraindicated, while consultation with a cardiologist specializing in congenital defects is recommended before altitude exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16825/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link\">",
"       \"Complications of scuba diving\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link&amp;anchor=H15#H15\">",
"       \"High altitude, air travel, and heart disease\", section on 'Congenital heart disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The characteristic finding in ASDs with large left-to-right shunts and normal pulmonary artery pressure is wide, fixed splitting of the second sound (S2), in contrast to the normal variation in splitting during the respiratory cycle.",
"     </li>",
"     <li>",
"      Echocardiography is the imaging modality of choice for the diagnosis of ASD. Transthoracic echocardiography is usually definitive in ostium secundum defects, while transesophageal echocardiography may aid in the sizing of defects, the diagnosis of sinus venosus defects, and the assessment of associated congenital anomalies such as anomalous pulmonary venous drainage or other abnormalities such as mitral valve prolapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30415976\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. Susan Wiegers for her contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/1\">",
"      Levin AR, Spach MS, Boineau JP, et al. Atrial pressure-flow dynamics in atrial septal defects (secundum type). Circulation 1968; 37:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/2\">",
"      Gutgesell HP, Huhta JC. Cardiac septation in atrioventricular canal defect. J Am Coll Cardiol 1986; 8:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/3\">",
"      al Zaghal AM, Li J, Anderson RH, et al. Anatomical criteria for the diagnosis of sinus venosus defects. Heart 1997; 78:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/4\">",
"      Attenhofer Jost CH, Connolly HM, Danielson GK, et al. Sinus venosus atrial septal defect: long-term postoperative outcome for 115 patients. Circulation 2005; 112:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/5\">",
"      Van Praagh S, Geva T, Lock JE, et al. Biatrial or left atrial drainage of the right superior vena cava: anatomic, morphogenetic, and surgical considerations--report of three new cases and literature review. Pediatr Cardiol 2003; 24:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/6\">",
"      Rostad H, S&ouml;rland S. Atrial septal defect of secundum type in patients under 40 years of age. A review of 481 operated cases. Symptoms, signs, treatment and early results. Scand J Thorac Cardiovasc Surg 1979; 13:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/7\">",
"      Manning PB, Mayer JE Jr, Sanders SP, et al. Unique features and prognosis of primum ASD presenting in the first year of life. Circulation 1994; 90:II30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/8\">",
"      Radzik D, Davignon A, van Doesburg N, et al. Predictive factors for spontaneous closure of atrial septal defects diagnosed in the first 3 months of life. J Am Coll Cardiol 1993; 22:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/9\">",
"      McMahon CJ, Feltes TF, Fraley JK, et al. Natural history of growth of secundum atrial septal defects and implications for transcatheter closure. Heart 2002; 87:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/10\">",
"      John Sutton MG, Tajik AJ, McGoon DC. Atrial septal defect in patients ages 60 years or older: operative results and long-term postoperative follow-up. Circulation 1981; 64:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/11\">",
"      Konstantinides S, Geibel A, Olschewski M, et al. A comparison of surgical and medical therapy for atrial septal defect in adults. N Engl J Med 1995; 333:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/12\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/13\">",
"      Giardini A, Donti A, Formigari R, et al. Determinants of cardiopulmonary functional improvement after transcatheter atrial septal defect closure in asymptomatic adults. J Am Coll Cardiol 2004; 43:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/14\">",
"      Berger F, Vogel M, Kramer A, et al. Incidence of atrial flutter/fibrillation in adults with atrial septal defect before and after surgery. Ann Thorac Surg 1999; 68:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/15\">",
"      Gatzoulis MA, Freeman MA, Siu SC, et al. Atrial arrhythmia after surgical closure of atrial septal defects in adults. N Engl J Med 1999; 340:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/16\">",
"      Popio KA, Gorlin R, Teichholz LE, et al. Abnormalities of left ventricular function and geometry in adults with an atrial septal defect. Ventriculographic, hemodynamic and echocardiographic studies. Am J Cardiol 1975; 36:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/17\">",
"      Ferlinz J. Left ventricular function in atrial septal defect: are interventricular interactions still too complex to permit definitive analysis? J Am Coll Cardiol 1988; 12:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/18\">",
"      Walker RE, Moran AM, Gauvreau K, Colan SD. Evidence of adverse ventricular interdependence in patients with atrial septal defects. Am J Cardiol 2004; 93:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/19\">",
"      Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001; 38:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/20\">",
"      Harvey JR, Teague SM, Anderson JL, et al. Clinically silent atrial septal defects with evidence for cerebral embolization. Ann Intern Med 1986; 105:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/21\">",
"      Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke 2002; 33:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/22\">",
"      Khositseth A, Cabalka AK, Sweeney JP, et al. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. Mayo Clin Proc 2004; 79:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/23\">",
"      Anzola GP, Magoni M, Guindani M, et al. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 1999; 52:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/24\">",
"      Steele PM, Fuster V, Cohen M, et al. Isolated atrial septal defect with pulmonary vascular obstructive disease--long-term follow-up and prediction of outcome after surgical correction. Circulation 1987; 76:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/25\">",
"      Vogel M, Berger F, Kramer A, et al. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart 1999; 82:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/26\">",
"      Waddell TK, Bennett L, Kennedy R, et al. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002; 21:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/27\">",
"      Gdalia J, Chollet D, Vedel J. Atrial septal defect with cyanosis without pulmonary hypertension or anomalous systemic venous drainage to the left atrium. Int J Cardiol 1988; 21:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/28\">",
"      Davia JE, Cheitlin MD, Bedynek JL. Sinus venosus atrial septal defect: analysis of fifty cases. Am Heart J 1973; 85:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/29\">",
"      Heller J, Hag&egrave;ge AA, Besse B, et al. \"Crochetage\" (notch) on R wave in inferior limb leads: a new independent electrocardiographic sign of atrial septal defect. J Am Coll Cardiol 1996; 27:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/30\">",
"      Sanders C, Bittner V, Nath PH, et al. Atrial septal defect in older adults: atypical radiographic appearances. Radiology 1988; 167:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16825/abstract/31\">",
"      Cirillo RL Jr. The scimitar sign. Radiology 1998; 206:623.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1418 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16825=[""].join("\n");
var outline_f16_27_16825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2556994\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Secundum ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primum ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sinus venosus ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coronary sinus ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patent foramen ovale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Atrial arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Stroke due to paradoxical embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Migraine headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pulmonary hypertension and Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cyanosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Scuba diving and altitude exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Precordial palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Heart sounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Heart murmurs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ELECTROCARDIOGRAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      CHEST X-RAY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2556994\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30415976\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1418\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1418|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/5/28755\" title=\"diagnostic image 1\">",
"      Atrial septal defect PA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1418|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/17/23826\" title=\"figure 1\">",
"      Pathophysiology ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/6/2153\" title=\"figure 2\">",
"      Atrial septal embryology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/36/7748\" title=\"figure 3\">",
"      Atrial septal defect anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1418|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/23/34174\" title=\"picture 1\">",
"      Finger clubbing cyanosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1418|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?6/56/7040\" title=\"movie 1\">",
"      TTE two ASDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?22/39/23167\" title=\"movie 2\">",
"      TEE ASD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=related_link\">",
"      Evaluation and prognosis of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=related_link\">",
"      High altitude, air travel, and heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5896?source=related_link\">",
"      Identification and assessment of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=related_link\">",
"      Management and outcome of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=related_link\">",
"      Management of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=related_link\">",
"      Patent foramen ovale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_27_16826="Metformin for treatment of the polycystic ovary syndrome";
var content_f16_27_16826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metformin for treatment of the polycystic ovary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16826/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16826/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16826/contributors\">",
"     David A Ehrmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16826/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16826/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16826/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/27/16826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/27/16826/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/27/16826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polycystic ovary syndrome (PCOS) is an important cause of both menstrual irregularity and androgen excess in women. When fully expressed, the manifestations include irregular menstrual cycles, hirsutism, obesity, and a constellation of cardiometabolic disturbances. It is a common endocrinopathy, occurring in 5 to 7 percent of reproductive age women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    in the management of PCOS will be reviewed here. The clinical manifestations, diagnosis, and other treatment options for PCOS are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INSULIN RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of PCOS has not been fully characterized. Many have evidence of abnormal LH secretion (increased LH pulse amplitude and frequency), and a significant percentage of women with PCOS display insulin resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of insulin resistance and increased LH secretion appears to stimulate ovarian androgen production. In addition, elevated insulin levels inhibit hepatic synthesis of sex hormone binding globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/4\">",
"     4",
"    </a>",
"    ]. These changes result in increased bioavailability of free androgens. The molecular defects that cause insulin resistance have not been fully determined. In some patients, insulin resistance appears related to mutations in the insulin receptor gene that result in abnormal function of the insulin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/5\">",
"     5",
"    </a>",
"    ]. Genetic defects leading to extreme levels of insulin resistance in women (eg, those resulting from mutations in the insulin receptor gene) are typically accompanied by manifestations of PCOS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40568?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\", section on 'Insulin secretion and action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dysregulation of local follicle regulatory systems by androgens and other factors impedes normal follicular growth, resulting in follicular arrest at the 4 to 8 mm diameter size [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/6\">",
"     6",
"    </a>",
"    ]. A dominant follicle (ie, 18 to 25 mm in diameter) does not develop and, therefore, ovulation does not occur. Thus, the combination of elevated LH, hyperinsulinemia, ovarian androgen overproduction, and disruption of follicle growth produces the PCOS phenotype of oligoovulation and hyperandrogenism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     METFORMIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    's major effect is to decrease hepatic glucose production thus reducing the need for insulin secretion; it also decreases intestinal absorption of glucose and modestly improves insulin sensitivity (increases peripheral glucose uptake and utilization). Metformin also has an antilipolytic effect that lowers fatty acid concentrations, thus reducing gluconeogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a molecular level,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    increases the activity of the enzyme AMP-activated protein kinase (AMPK) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Metformin appears to work through the Peutz-Jeghers protein, LKB1, to regulate AMPK [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/12\">",
"     12",
"    </a>",
"    ]. It is used primarily for the treatment of type 2 diabetes, but has also been used in women with PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical pharmacology of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    has been reviewed in a number of publications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The drug is a biguanide anti-hyperglycemic approved by the United States Food and Drug Administration (FDA) for management of type 2 diabetes mellitus when hyperglycemia cannot be managed by diet and exercise alone. Unlike sulfonylureas, it does not produce hypoglycemia in either normal subjects or patients with type 2 diabetes. The American Diabetes Association also recommends consideration of metformin for diabetes prevention in individuals with confirmed impaired fasting glucose",
"    <strong>",
"     and",
"    </strong>",
"    impaired glucose tolerance who are less than 60 years of age and with a BMI &gt;35",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link\">",
"     \"Metformin in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H20#H20\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Metformin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    is rapidly absorbed from the small intestine with peak plasma levels occurring two hours after ingestion. Food decreases the rate of drug absorption and peak drug concentration. Metformin is not metabolized and is largely excreted in the urine. Renal clearance is approximately 3.5 times greater than renal clearance of creatinine, which indicates that tubular secretion is the main route of excretion. The plasma elimination half-life is approximately six hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    is available in a generic form as 500, 850, and 1000 mg tablets. The target dose is 1500 to 2550 mg daily; clinically significant responses are not regularly observed at doses less than 1000 mg daily. Many clinicians begin treatment with 500 mg taken with a meal, to reduce gastrointestinal side effects. If tolerated, the dose can be increased to 500 mg at both lunch and dinner, and then to 500 mg at breakfast, lunch, and dinner. One to two weeks should elapse between increases in dose.",
"   </p>",
"   <p>",
"    Two extended release formulations are available: Glucophage XR and generic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    ER. When using extended release tablets, the entire daily dose is given at dinner time. The initial dose is 500 mg with dinner, with escalation to a maximum of 2000 mg once daily. Extended release metformin may be associated with fewer side effects, and in general we suggest starting with these formulations rather than the short acting ones. For patients who cannot tolerate once-daily dosing of the",
"    <span class=\"nowrap\">",
"     XR/ER",
"    </span>",
"    formulations, it is acceptable to split the dose in an effort to further minimize side effects.",
"   </p>",
"   <p>",
"    Finally,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    exists in both a liquid formulation (Riomet&reg;) and a specially-formulated tablet (Glumetza&reg;) designed to release the medication more slowly into the intestinal tract. In instances where the traditional formulations are not tolerated, it is occasionally helpful to have the patient try either the liquid or slow release formulation before abandoning metformin therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects are gastrointestinal: diarrhea, nausea or vomiting, flatulence, indigestion, and abdominal discomfort. These may be caused by high intestinal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    concentrations that cause build up of lactic acid in the bowel wall [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/18\">",
"     18",
"    </a>",
"    ]. No significant histological changes in the bowel mucosa have been identified in laboratory animals taking metformin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/19\">",
"     19",
"    </a>",
"    ]. In one study, a dose of 2550 mg daily was associated with diarrhea in 53 percent of patients taking metformin versus 12 percent of the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/20\">",
"     20",
"    </a>",
"    ]. The frequency of",
"    <span class=\"nowrap\">",
"     nausea/vomiting",
"    </span>",
"    was also higher in the metformin group, 26 and 8 percent, respectively. Nevertheless, only about 5 percent of patients discontinue the medication due to side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactic acidosis has been described, but it is an extremely rare complication in otherwise healthy individuals. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    should not be prescribed for women with other conditions that increase the risk of lactic acidosis, such as renal insufficiency, congestive heart failure or sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link&amp;anchor=H7#H7\">",
"     \"Metformin in the treatment of diabetes mellitus\", section on 'Lactic acidosis'",
"    </a>",
"    .) Prior to initiating metformin treatment, a normal serum creatinine (less than 1.4",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    should be confirmed, since metformin is excreted by the kidney.",
"   </p>",
"   <p>",
"    In patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , intravascular contrast studies with iodinated materials may lead to changes in renal function and have been associated with lactic acidosis. The FDA-approved package insert now includes a recommendation that for patients in whom radiologic studies involving the use of iodinated contrast materials are planned (eg, intravenous urogram, intravenous cholangiography, angiography and computed tomography [CT] scans with intravascular contrast materials), metformin should be discontinued at the time of or prior to the procedure and withheld for 48 hours after the procedure and resumed only after renal function has been shown to be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/23\">",
"     23",
"    </a>",
"    ]. However, it may be safe to give other types of contrast media to persons taking metformin, as long as renal function is known to be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    therapy should be temporarily suspended for all surgical procedures that involve restriction of fluid intake and should not be restarted until normal fluid intake has resumed and renal function has been shown to be normal.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     Cimetidine",
"    </a>",
"    competes for renal clearance with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and will cause an increase in metformin levels; therefore, concomitant administration should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/25\">",
"     25",
"    </a>",
"    ]. Other drug interactions are detailed in the drug database.",
"   </p>",
"   <p>",
"    Ten to 30 percent of patients develop vitamin B12 malabsorption with decreased serum concentration of vitamin B12 and holotranscobalamin, the bioavailable form of vitamin B12 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/26\">",
"     26",
"    </a>",
"    ]. The mechanism appears to be",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    interference with intestinal intracellular calcium metabolism, thereby blocking calcium dependent absorption of vitamin B12 in the ileum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/27\">",
"     27",
"    </a>",
"    ]. However, development of anemia is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/26\">",
"     26",
"    </a>",
"    ]; annual measurement of red blood cell B12 concentration is adequate monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, treatment of type 2 diabetes mellitus is the only indication for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    administration approved by the FDA. Nevertheless, it has been used \"off-label\" to treat or prevent several clinical problems associated with PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oligomenorrhea",
"     </li>",
"     <li>",
"      Hirsutism",
"     </li>",
"     <li>",
"      Infertility",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Prevention of type 2 diabetes mellitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, small observational studies have shown benefits for prevention of gestational diabetes and reducing the risk of early miscarriage in pregnant women with PCOS. Although it might be preferable to treat only insulin-resistant women with PCOS, there is currently no readily available, reliable test to evaluate the presence of insulin resistance. Some clinicians do not test at all; others perform an oral glucose tolerance test to look for impaired glucose tolerance and check for elevated insulin levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oligomenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with oligomenorrhea due to PCOS who need endometrial protection, we suggest estrogen-progestin contraceptives as first-line therapy. Therapeutic effects include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decrease in LH secretion and a resulting decrease in ovarian androgen production",
"     </li>",
"     <li>",
"      An increase in hepatic production of sex-hormone binding globulin with a decrease in bioavailable testosterone",
"     </li>",
"     <li>",
"      A decrease in adrenal androgen secretion",
"     </li>",
"     <li>",
"      Regular withdrawal bleeding",
"     </li>",
"     <li>",
"      Prevention of endometrial hyperplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27928?source=see_link\">",
"     \"Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For second line therapy and for situations where estrogen-progestin contraceptives are contraindicated, we suggest continuous or cyclic progestin-only treatment for endometrial protection.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    may also be used as second-line therapy (particularly in women with contraindications to pill use), but it has not been proven to be endometrial protective. Metformin will restore ovulatory menses in approximately 50 percent of women with PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], although some studies report ovulatory rates from 23 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/31-38\">",
"     31-38",
"    </a>",
"    ]. When metformin is used, cyclic progestin therapy is added for the first six months of metformin treatment, until regular cycles are established.",
"   </p>",
"   <p>",
"    Estrogen-progestin contraceptives may worsen insulin resistance in some women with PCOS; whether this phenomenon is clinically important remains unclear. In particular, the risk of developing diabetes mellitus appears not to be increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of polycystic ovary syndrome in adults\", section on 'OCs and insulin sensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one trial, 23 women with PCOS were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    (500 mg three times per day) or placebo for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/29\">",
"     29",
"    </a>",
"    ]. Approximately one-half of the women achieved normalization of menstrual function, confirmed by intermenstrual interval and luteal phase serum progesterone monitoring. In a meta-analysis of 13 trials, women treated with metformin had a fourfold higher chance of ovulating than women treated with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/14\">",
"     14",
"    </a>",
"    ]. A similar fourfold increase was seen for the combination of metformin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    when compared with clomiphene alone.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    may restore ovulation in some women, it appears to be less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    for pregnancy and live birth rates. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Anovulatory infertility'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Metabolic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a trial described above [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/29\">",
"     29",
"    </a>",
"    ], compared with placebo, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    group had improvement in plasma insulin and insulin sensitivity (as measured by glucose clamp studies), a reduction in serum free testosterone, and an increase in mean serum HDL cholesterol. Both the biochemical and clinical changes were independent of changes in body weight and were sustained in a follow-up open long-term observational study (mean duration of treatment was 11 months). However, there was no significant reduction in hirsutism, despite the lower free serum testosterone concentration.",
"   </p>",
"   <p>",
"    A second 14-week trial in 94 women with PCOS randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or placebo showed similar clinical and metabolic benefits, with the exception of the most obese women (body mass index [BMI] &gt;37",
"    <span class=\"nowrap\">",
"     kg/m)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/31\">",
"     31",
"    </a>",
"    ]. A meta-analysis of 13 trials reported that metformin is associated with a reduction in blood pressure, LDL, and fasting insulin levels, when compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Endometrial effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some women may have restoration of menses, unless cycles are regular and ovulatory, one cannot assume that the patient has reliable endometrial protection. Some women do not ovulate during the first six months of treatment and, therefore, we recommend cyclic progestin treatment during this interval. For those who begin to have menses that are not regular and ovulatory, cyclic progestins or oral contraceptives are necessary.",
"   </p>",
"   <p>",
"    Women who do not attain regular ovulatory menses should probably be treated with cyclic progestin therapy to reduce the risk of endometrial hyperplasia, until regular menses are established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=see_link\">",
"     \"Classification and diagnosis of endometrial hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A contraceptive (eg, diaphragm, condom) should be prescribed for all sexually active women not planning pregnancy since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    treatment may induce ovulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Dose and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimum dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    to restore ovulatory menses has not been determined. The two best studied metformin regimens are 500 mg three times daily (1500 mg daily) and 850 mg twice daily (1700 mg daily). Some authorities believe that women with PCOS who do not respond at these doses should be treated with 2000 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/39\">",
"     39",
"    </a>",
"    ]. Extended release preparations can also be used (500 mg tablets, with the entire dose of 1500 to 2000 mg administered with dinner).",
"   </p>",
"   <p>",
"    After initiating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    therapy, it may take up to six months for ovulatory cycles to ensue. During the initial phase of oligomenorrhea, it may be difficult to determine if ovulation has taken place. Measuring serum progesterone every 10 days may be one approach, although cumbersome, to identify if ovulation has occurred following initiation of metformin therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hirsutism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first-line therapy for treatment of hirsutism caused by PCOS is an estrogen-progestin contraceptive, as recommended by the 2008 Endocrine Society Guidelines. An antiandrogen is then added after six months if the cosmetic response is suboptimal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of clinical trials have examined the effects of insulin-lowering agents on circulating androgen concentrations in women with PCOS and have noted a reduction in these hormones with therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/29,40-46\">",
"     29,40-46",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    may reduce serum androgen concentrations, it has limited benefit for the treatment of hirsutism [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/47-53\">",
"     47-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized clinical trial, 31 nonobese (mean BMI 21.9",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      adolescents (mean age 18.7 years) with PCOS and hirsutism received either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (1275 mg daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"       flutamide",
"      </a>",
"      , or both for nine months [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/47\">",
"       47",
"      </a>",
"      ]. Compared with monotherapy, flutamide plus metformin therapy resulted in greater improvement in insulin sensitivity, dyslipidemia, and serum testosterone, androstenedione, and DHEA-S concentrations. The Ferriman-Gallwey hirsutism scores improved in all three groups, with reductions of 31, 51, and 44 percent, respectively.",
"     </li>",
"     <li>",
"      Other studies have shown more modest benefits [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/48-52\">",
"       48-52",
"      </a>",
"      ] or none at all [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The best available evidence comes from a meta-analysis of nine placebo-controlled trials of insulin-lowering drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/54\">",
"       54",
"      </a>",
"      ]. For all nine trials combined, a small effect on hirsutism was observed (weighted mean difference for decrease in Ferriman-Gallwey score was -1.5). The benefit was largely due to a trial of troglitazone, a thiazolidinedione that was withdrawn from the market because of hepatotoxicity. When the eight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      trials were analyzed separately, no significant benefit was seen. Based upon these findings, the Endocrine Society Clinical Practice Guidelines suggest against the routine use of metformin for the treatment of hirsutism [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anovulatory infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;A structured approach, starting with low-cost interventions and advancing to high resource interventions, is warranted for treatment of anovulatory infertility in women with PCOS (",
"    <a class=\"graphic graphic_table graphicRef56718 \" href=\"UTD.htm?4/36/4684\">",
"     table 1",
"    </a>",
"    ). The first two management steps are weight loss through caloric restriction and increased exercise for women with a BMI &gt;27",
"    <span class=\"nowrap\">",
"     kg/m,",
"    </span>",
"    followed by medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of polycystic ovary syndrome in adults\", section on 'Ovulation induction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early ovulation induction trials suggested better results with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    alone or metformin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    when compared with clomiphene alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/14,29-36,41,56-58\">",
"     14,29-36,41,56-58",
"    </a>",
"    ]. A 2012 trial reported higher live birth rates with three months of metformin pretreatment when compared with placebo; the benefit was greatest for obese women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, data from a number of multicenter trials have now reported that while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    may be effective for restoring ovulation, it appears to be less effective for fertility (live birth rates) when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/60-66\">",
"     60-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2012 meta-analysis of 38",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    trials in 3495 women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/67\">",
"     67",
"    </a>",
"    ], metformin monotherapy was associated with an improvement in pregnancy rates when compared with placebo (pooled OR 2.31, 95% CI 1.52-3.51), but not live birth rates (OR 1.80; 95% CI 0.52-6.16). In the studies that compared metformin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    monotherapy, there was evidence of an improved live birth rate in the group of obese women who took clomiphene (OR 0.3 95% CI 0.17-0.52 for metformin versus clomiphene).",
"   </p>",
"   <p>",
"    Thus, larger trials and a meta-analysis suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    is more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    for live-birth rates, the most relevant outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/60\">",
"     60",
"    </a>",
"    ], and that the addition of metformin to clomiphene does not provide additional benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. However, in one of the trials, multiple pregnancy rates were higher with clomiphene [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A consensus group has recommended against the routine use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    except in women with glucose intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/68\">",
"     68",
"    </a>",
"    ]. However, the addition of metformin in some women may help facilitate weight loss and, therefore, ovulation. In addition, metformin may provide additional metabolic effects in some women that are beneficial for pregnancy. Additional information on ovulation induction in these patients is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link&amp;anchor=H31#H31\">",
"     \"Ovulation induction with clomiphene citrate\", section on 'Infertility in PCOS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=see_link\">",
"     \"Strategies for improving the efficacy of clomiphene induction of ovulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    therapy also appears to be similar to laparoscopic ovarian diathermy (LOD) for inducing ovulation, but better for overall reproductive outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=see_link\">",
"     \"Laparoscopic surgery for ovulation induction in polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Effect on gonadotropin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    administration prior to ovulation induction with recombinant FSH resulted in a greater likelihood of mono-ovulatory cycles in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/70\">",
"     70",
"    </a>",
"    ]. However, in a second trial, the addition of metformin had no effect on ovarian response to FSH when compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     IVF pretreatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with PCOS, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    before or during IVF cycles does not appear to improve clinical pregnancy or live birth rates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. However, metformin administration before or during IVF cycles does appear to reduce the risk of ovarian hyperstimulation (OHSS) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Similar estimates of benefits were reported in two meta-analyses (odds ratio 0.27 for risk of OHSS with metformin compared with placebo use) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22647?source=see_link\">",
"     \"Prevention of ovarian hyperstimulation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 50 percent of women with PCOS are obese.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    may be useful for achieving weight loss or potentiating weight loss achieved by caloric restriction. As an example, a large clinical trial randomly assigned 150 obese women to receive appetite suppressants (sibutramine 10 mg twice daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    120 mg three times daily) or metformin (850 mg twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/75\">",
"     75",
"    </a>",
"    ]. After six months of treatment, all three groups had 9 to 14 percent reductions in BMI. Thus, metformin treatment was associated with as much weight reduction as other obesity medications. Of note, sibutramine is no longer available in the US or Canada. It was withdrawn from the market because of clinical trial data that suggested an increased risk of heart attack and stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    (850 mg twice daily) plus a low calorie diet (1200 to 1400 kcal daily) was superior to a low calorie diet alone in facilitating weight loss in obese women with and without PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/77\">",
"     77",
"    </a>",
"    ]. Other investigators have reported similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. One trial reported that higher dose metformin (2550",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was more effective for weight loss than lower dose metformin (1500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in obese women with PCOS. The dose-dependent effect was observed in women with a BMI between 30 and 37",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    but not in those whose BMI was greater than 37",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    resulted in a similar amount of weight loss in the study noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/75\">",
"     75",
"    </a>",
"    ], orlistat was significantly better than metformin in a three-month study of 21 obese PCOS patients (mean percentage weight loss 4.7 versus 1.02 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/81\">",
"     81",
"    </a>",
"    ]. Serum testosterone concentrations decreased to a similar degree in both groups. Effects on ovulatory status were not reported.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    appears to decrease caloric intake by suppressing appetite [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/82\">",
"     82",
"    </a>",
"    ]. This effect may be independent of its gastrointestinal side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Side effects'",
"    </a>",
"    above.) Interestingly, metformin-induced weight loss appears to preferentially involve adipose tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/84\">",
"     84",
"    </a>",
"    ]. In contrast, insulin and other antihyperglycemic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    are associated with weight gain. As an example, diabetics treated with insulin, glyburide, or chlorpropamide had an average weight gain of 3.5 to 4.8 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/85\">",
"     85",
"    </a>",
"    ], while treatment with pioglitazone and rosiglitazone was associated with weight gain of 2 to 4 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/86\">",
"     86",
"    </a>",
"    ]. Given the importance of avoiding weight gain in women with PCOS, metformin appears to have a unique advantage compared with other insulin sensitizing agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with PCOS are at increased risk for developing type 2 diabetes mellitus or impaired glucose tolerance. In a study of 122 obese women with PCOS, 45 percent had either impaired glucose tolerance (IGT; 35 percent) or type 2 diabetes mellitus (10 percent) by age 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/87\">",
"     87",
"    </a>",
"    ]. As is the case in non-PCOS populations, the risk of type 2 diabetes in PCOS appears to be highest among those who are obese",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have a significant family history of type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/87\">",
"     87",
"    </a>",
"    ]. The frequency of diagnosis of type 2 diabetes in women with PCOS varies with the screening test used. A fasting blood glucose may underestimate the prevalence of diabetes when compared with an oral glucose tolerance test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\", section on 'Type 2 diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both lifestyle interventions and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    are effective in men and women with IGT for the prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diet and exercise were more effective than metformin. However, the American Diabetes Association now recommends consideration of metformin for diabetes prevention in individuals with confirmed impaired fasting glucose",
"    <strong>",
"     and",
"    </strong>",
"    impaired glucose tolerance who are less than 60 years of age and with a BMI &gt;35",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective data in women with PCOS suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    therapy may delay or prevent conversion to impaired glucose tolerance and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/88\">",
"     88",
"    </a>",
"    ]. However, in the absence of clinical trial data, we do not recommend metformin for women with normal glucose tolerance for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Spontaneous abortion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spontaneous abortion rate in women with PCOS is 20 to 40 percent higher than the baseline in the general obstetric population [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/89\">",
"     89",
"    </a>",
"    ]. No trials have been performed to specifically address the impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    therapy on the primary endpoint of pregnancy loss. Three studies in women with PCOS reported miscarriage rates of 62 to 73 percent in pregnancies when metformin was not taken and 9 to 36 percent of pregnancies in the same women when metformin was taken [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. However, in a meta-analysis of 17 trials in women with PCOS taking metformin with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    for ovulation induction, no effect of metformin was seen on the risk of pregnancy loss [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167683613\">",
"    <span class=\"h3\">",
"     Gestational diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of gestational diabetes is several-fold higher in women with PCOS than in the general obstetric population [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/92,94\">",
"     92,94",
"    </a>",
"    ]. Two observational studies suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    use was associated with a lower risk of gestational diabetes (GDM), but this was not confirmed in a trial of 273 pregnancies among 257 women with PCOS who were randomly assigned to receive metformin (2000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo from the first trimester until delivery. There was no significant difference in prevalence of GDM between groups (metformin 17.6 percent versus placebo 16.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of established gestational diabetes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link&amp;anchor=H18999792#H18999792\">",
"     \"Medical management and follow-up of gestational diabetes mellitus\", section on 'Metformin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the same randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    versus placebo during pregnancy, no significant differences were seen in the prevalence of preeclampsia (7.4 versus 3.7 percent) or preterm delivery (3.7 versus 8.2 percent), or a composite outcome that included preeclampsia, preterm delivery, and gestational diabetes (overall rate of complications 25.9 and 24.4 percent for metformin and placebo, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/95\">",
"     95",
"    </a>",
"    ]. Women taking metformin gained less weight than women in the placebo group (mean difference - 2.2 kg).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Neonatal outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of pregnancy outcome in 172 women after first trimester exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    did not find an increased risk of major malformations when compared with control women (OR 0.50, 95% CI 0.15-1.60) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link&amp;anchor=H18999792#H18999792\">",
"     \"Medical management and follow-up of gestational diabetes mellitus\", section on 'Metformin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167683777\">",
"    <span class=\"h3\">",
"     Breast feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of breast-fed versus formula-fed infants of mothers with PCOS on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , no adverse developmental outcomes were observed in the breast-fed when compared with formula-fed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Available data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is ineffective for reducing the risk of early pregnancy loss in women with PCOS. In addition, metformin use during pregnancy does not appear to prevent gestational diabetes. We therefore suggest against the use of metformin for either indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     METFORMIN PLUS ORAL CONTRACEPTIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently inadequate evidence to recommend the routine addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    to oral contraceptive therapy, as it is still unclear whether this combination has important cosmetic or metabolic advantages over oral contraceptive monotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized clinical trial, 40 nonobese women with PCOS were treated with either an oral contraceptive alone (ethinyl estradiol 35",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"       cyproterone acetate",
"      </a>",
"      2",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or this oral contraceptive plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (500 mg three times daily) for four months [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/98\">",
"       98",
"      </a>",
"      ]. Combination therapy of the oral contraceptive plus metformin resulted in the greatest reduction of the serum androstenedione level and the greatest increase in sex hormone binding globulin (",
"      <a class=\"graphic graphic_figure graphicRef56361 \" href=\"UTD.htm?34/11/35005\">",
"       figure 1",
"      </a>",
"      ). Weight loss only occurred in the group taking metformin. Circulating androgen concentrations and Ferriman-Gallwey hirsutism scores decreased from baseline in both groups. Thus, the combination of metformin plus an oral contraceptive may be especially useful when an important treatment objective is weight loss, but may not be warranted for the sole purpose of treating hirsutism.",
"     </li>",
"     <li>",
"      In a second trial, 30 women with PCOS were randomly assigned to receive an oral contraceptive alone (ethinyl estradiol 35",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      plus norgestimate 25",
"      <span class=\"nowrap\">",
"       mcg/day)",
"      </span>",
"      or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (1500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for six months [",
"      <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/99\">",
"       99",
"      </a>",
"      ]. Although obese women were not specifically excluded, the population was relatively lean (mean BMI &plusmn; SD 22.1 &plusmn; 3.1 and 24.7 &plusmn; 4.9",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      in the monotherapy and combined therapy groups, respectively). At six months, the only significant difference between the groups was a lower free androgen index in the combination compared with the monotherapy group. No differences were seen in lipids, insulin sensitivity (measured by euglycemic hyperinsulinemic clamp technique), SHBG, or testosterone. It is possible that results would be different in an obese population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     METFORMIN VERSUS ORAL CONTRACEPTIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, combination estrogen-progestin contraceptive are the first-line option for treatment of oligomenorrhea or hyperandrogenism in women with PCOS, when fertility is not an active goal. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Oligomenorrhea'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There has been concern that estrogen-progestin contraceptives may have adverse metabolic effects in women with PCOS, in particular, a worsening of insulin sensitivity. However, as noted in the trial described above, oral contraceptives were less beneficial for insulin sensitivity, but better for androgen suppression and menstrual cycle control [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/53\">",
"     53",
"    </a>",
"    ]. In a meta-analysis of four trials that included 104 women with PCOS,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    was less effective than oral contraceptives for improving menstrual pattern and in reducing serum total testosterone concentration, but more effective for reducing fasting insulin and not increasing fasting triglyceride concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/27/16826/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28115?source=see_link\">",
"       \"Patient information: Polycystic ovary syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"       \"Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    for the management of women with PCOS depends on the individual patient's goals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with oligomenorrhea who need",
"      <strong>",
"       endometrial protection",
"      </strong>",
"      , we suggest estrogen-progestin contraceptives as first-line therapy rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For second line therapy and for situations where estrogen-progestin contraceptives are contraindicated we suggest continuous or cyclic progestin-only treatment for endometrial protection. Metformin may also be used as second-line therapy (particularly in women with contraindications to pill use), but it has not been proven to be endometrial protective. When metformin is used cyclic progestin therapy may be added for the first six months of metformin treatment, until regular cycles are established.",
"     </li>",
"     <li>",
"      For management of hyperandrogenic symptoms alone, we suggest estrogen-progestin contraceptives as first line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other options are reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"       \"Treatment of hirsutism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women who desire",
"      <strong>",
"       pregnancy",
"      </strong>",
"      , we suggest weight loss (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (We suggest this to all women with PCOS who are overweight or obese.) If they are unable to lose weight or modest weight loss does not restore ovulatory cycles, we suggest ovulation induction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Anovulatory infertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      is not a",
"      <strong>",
"       weight loss",
"      </strong>",
"      drug per se, it is a reasonable adjunct to diet and exercise for obese women with PCOS. We do not recommend its use in obese women who do not have PCOS.",
"     </li>",
"     <li>",
"      For women with PCOS who are found to have",
"      <strong>",
"       type 2 diabetes mellitus",
"      </strong>",
"      or impaired glucose tolerance, the management is the same as other non-PCOS patients with these disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"       \"Overview of medical care in adults with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest against the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      during pregnancy to prevent gestational diabetes",
"      <strong>",
"      </strong>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <strong>",
"      </strong>",
"      We also suggest against the routine use or metformin to prevent pregnancy loss in women with PCOS",
"      <strong>",
"      </strong>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <strong>",
"      </strong>",
"      Its role in this setting is not well established.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/1\">",
"      Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83:3078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/2\">",
"      Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84:4006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/3\">",
"      Asunci&oacute;n M, Calvo RM, San Mill&aacute;n JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/4\">",
"      Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/5\">",
"      Legro RS, Strauss JF. Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 2002; 78:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/6\">",
"      Fujiwara T, Sidis Y, Welt C, et al. Dynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles. J Clin Endocrinol Metab 2001; 86:4206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/7\">",
"      Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/8\">",
"      Patan&egrave; G, Piro S, Rabuazzo AM, et al. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2000; 49:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/9\">",
"      Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/10\">",
"      Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277:25226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/11\">",
"      Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002; 51:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/12\">",
"      Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/13\">",
"      Harborne L, Fleming R, Lyall H, et al. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003; 361:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/14\">",
"      Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; :CD003053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/15\">",
"      Barbieri RL. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol 2003; 101:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/16\">",
"      Pugeat M, Ducluzeau PH. Insulin resistance, polycystic ovary syndrome and metformin. Drugs 1999; 58 Suppl 1:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/17\">",
"      Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/18\">",
"      Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994; 24:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/19\">",
"      Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol 2000; 59:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/20\">",
"      DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/21\">",
"      Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/22\">",
"      Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/23\">",
"      Moros, SK, Thomsen, HS. Adverse reactions to iodinated contrast media. European Radiol 2001; 11:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/24\">",
"      McCartney MM, Gilbert FJ, Murchison LE, et al. Metformin and contrast media--a dangerous combination? Clin Radiol 1999; 54:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/25\">",
"      Somogyi A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/26\">",
"      DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/27\">",
"      Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000; 23:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/28\">",
"      Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008; 358:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/29\">",
"      Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/30\">",
"      Unl&uuml;hizarci K, Keletimur F, Bayram F, et al. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1999; 51:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/31\">",
"      Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002; 87:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/32\">",
"      Vel&aacute;zquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/33\">",
"      Glueck CJ, Wang P, Fontaine R, et al. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999; 48:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/34\">",
"      Genazzani AD, Battaglia C, Malavasi B, et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/35\">",
"      Eisenhardt S, Schwarzmann N, Henschel V, et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2006; 91:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/36\">",
"      Essah PA, Apridonidze T, Iuorno MJ, Nestler JE. Effects of short-term and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 2006; 86:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/37\">",
"      Ib&aacute;&ntilde;ez L, Valls C, Ferrer A, et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001; 86:3595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/38\">",
"      Carmina E, Lobo RA. Does metformin induce ovulation in normoandrogenic anovulatory women? Am J Obstet Gynecol 2004; 191:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/39\">",
"      Nestler JE, Stovall D, Akhter N, et al. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002; 77:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/40\">",
"      Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/41\">",
"      Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/42\">",
"      Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/43\">",
"      Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/44\">",
"      Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/45\">",
"      Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/46\">",
"      Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/47\">",
"      Ib&aacute;&ntilde;ez L, Valls C, Ferrer A, et al. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab 2002; 87:2870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/48\">",
"      Ib&aacute;&ntilde;ez L, Valls C, Potau N, et al. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000; 85:3526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/49\">",
"      Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/50\">",
"      Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/51\">",
"      Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002; 147:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/52\">",
"      Harborne L, Fleming R, Lyall H, et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:4116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/53\">",
"      Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000; 85:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/54\">",
"      Cosma M, Swiglo BA, Flynn DN, et al. Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008; 93:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/55\">",
"      Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/56\">",
"      George SS, George K, Irwin C, et al. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Hum Reprod 2003; 18:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/57\">",
"      Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002; 77:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/58\">",
"      Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/59\">",
"      Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab 2012; 97:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/60\">",
"      Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/61\">",
"      Moll E, Bossuyt PM, Korevaar JC, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006; 332:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/62\">",
"      Palomba S, Orio F Jr, Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:4068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/63\">",
"      Zain MM, Jamaluddin R, Ibrahim A, Norman RJ. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 2009; 91:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/64\">",
"      Johnson NP, Stewart AW, Falkiner J, et al. PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Hum Reprod 2010; 25:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/65\">",
"      Siebert TI, Viola MI, Steyn DW, Kruger TF. Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis. Gynecol Obstet Invest 2012; 73:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/66\">",
"      Misso ML, Costello MF, Garrubba M, et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2013; 19:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/67\">",
"      Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012; 5:CD003053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/68\">",
"      Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/69\">",
"      Palomba S, Orio F Jr, Nardo LG, et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:4801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/70\">",
"      Palomba S, Falbo A, Orio F Jr, et al. A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod 2005; 20:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/71\">",
"      Yarali H, Yildiz BO, Demirol A, et al. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 2002; 17:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/72\">",
"      Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2009; :CD006105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/73\">",
"      Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 2013; 120:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/74\">",
"      Palomba S, Falbo A, Carrillo L, et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in&nbsp;vitro fertilization cycles: a randomized, controlled trial. Fertil Steril 2011; 96:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/75\">",
"      Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4:49.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm (Accessed on October 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/77\">",
"      Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/78\">",
"      Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/79\">",
"      Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107:E55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/80\">",
"      Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005; 90:4593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/81\">",
"      Jayagopal V, Kilpatrick ES, Holding S, et al. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 2005; 90:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/82\">",
"      Yki-J&auml;rvinen H, Nikkil&auml; K, M&auml;kimattila S. Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. Drugs 1999; 58 Suppl 1:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/83\">",
"      Haupt E, Knick B, Koschinsky T, et al. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab 1991; 17:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/84\">",
"      Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/85\">",
"      Hermann LS, Scherst&eacute;n B, Bitz&eacute;n PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/86\">",
"      Fonseca VA, Valiquett TR, Huang SM, et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab 1998; 83:3169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/87\">",
"      Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/88\">",
"      Sharma ST, Wickham EP 3rd, Nestler JE. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract 2007; 13:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/89\">",
"      Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17:2858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/90\">",
"      Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/91\">",
"      Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001; 75:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/92\">",
"      Thatcher SS, Jackson EM. Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil Steril 2006; 85:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/93\">",
"      Palomba S, Falbo A, Orio F Jr, Zullo F. Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2009; 92:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/94\">",
"      Mikola M, Hiilesmaa V, Halttunen M, et al. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001; 16:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/95\">",
"      Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab 2010; 95:E448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/96\">",
"      Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 2006; 86:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/97\">",
"      Glueck CJ, Salehi M, Sieve L, Wang P. Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. J Pediatr 2006; 148:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/98\">",
"      Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002; 17:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/99\">",
"      Cibula D, Fanta M, Vrbikova J, et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod 2005; 20:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/27/16826/abstract/100\">",
"      Costello MF, Shrestha B, Eden J, et al. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007; 22:1200.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7411 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-CAE323FBD7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16826=[""].join("\n");
var outline_f16_27_16826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INSULIN RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      METFORMIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oligomenorrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Metabolic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Endometrial effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dose and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hirsutism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anovulatory infertility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Effect on gonadotropin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - IVF pretreatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Spontaneous abortion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H167683613\">",
"      - Gestational diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Other complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Neonatal outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H167683777\">",
"      - Breast feeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      METFORMIN PLUS ORAL CONTRACEPTIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      METFORMIN VERSUS ORAL CONTRACEPTIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7411\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7411|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/11/35005\" title=\"figure 1\">",
"      PCOS androstenedione on OCP versus OCP-metformin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7411|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/36/4684\" title=\"table 1\">",
"      Multistep approach treatment infertility PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40568?source=related_link\">",
"      Epidemiology and pathogenesis of the polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=related_link\">",
"      Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=related_link\">",
"      Medical management and follow-up of gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=related_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28115?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22647?source=related_link\">",
"      Prevention of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=related_link\">",
"      Strategies for improving the efficacy of clomiphene induction of ovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=related_link\">",
"      Treatment of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27928?source=related_link\">",
"      Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_27_16827="Obstetrical history 2";
var content_f16_27_16827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Obstetrical history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        History of any pregnancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of miscarriages, terminations, or ectopic pregnancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of assisted reproduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        For each pregnancy carried:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Date of delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gestational age at delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mode of delivery with indication for operative delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Maternal complications, such as hypertension or diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fetal complications, such as growth restriction, anomalies or stillbirth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Delivery or operative complications&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neonatal problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Current health of children",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16827=[""].join("\n");
var outline_f16_27_16827=null;
var title_f16_27_16828="Causes torsade de pointes";
var content_f16_27_16828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonantiarrhythmic agents which may induce torsade de pointes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Psychiatric drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pheniothiazines - thioridazine, chlorpromazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tricyclic antidepressants - amitriptyline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Haloperidol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antibiotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Azithromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chloroquine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pentamidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimethoprim-sulfamethoxazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Toxins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arsenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Organophosphate insecticides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Diuretics",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Terfenadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Astemizole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Calcium channel blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bepridil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lidoflazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antihyperlipidemics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Probucol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amantadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cisapride",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16828=[""].join("\n");
var outline_f16_27_16828=null;
var title_f16_27_16829="Megakaryocyte ploidy";
var content_f16_27_16829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Megakaryocyte ploidy varies inversely with the platelet count",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 321px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mice were made thrombocytopenic by the injection of antiplatelet antibody or thrombocytotic by the transfusion of platelets and 48 hours later compared with normal animals. Changes in the platelet count were associated with inverse changes in mean bone marrow megakaryocyte ploidy (r = 0.98).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kuter, DJ, Greenberg, SM, Rosenberg, RD, Blood 1989; 74:1952.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16829=[""].join("\n");
var outline_f16_27_16829=null;
var title_f16_27_16830="ATPIII LDL goals";
var content_f16_27_16830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82504%7ECARD%2F67460%7EPC%2F54585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82504%7ECARD%2F67460%7EPC%2F54585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ATP III LDL-cholesterol goals and cutpoints for therapeutic lifestyle changes and drug therapy in different risk categories",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Risk category",
"      </td>",
"      <td class=\"subtitle1\">",
"       LDL-cholesterol goal",
"      </td>",
"      <td class=\"subtitle1\">",
"       LDL-cholesterol level at which to initiate therapeutic lifestyle changes",
"      </td>",
"      <td class=\"subtitle1\">",
"       LDL-cholesterol level at which to consider drug therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coronary heart disease (CHD) or CHD risk equivalent (10-year risk &gt;20 percent)*",
"      </td>",
"      <td>",
"       &lt;100 mg/dL (2.58 mmol/L)",
"      </td>",
"      <td>",
"       &ge;100 mg/dL (2.58 mmol/L)",
"      </td>",
"      <td>",
"       &ge;130 mg/dL (3.36 mmol/L); drug optional at 100 to 129 mg/dL (2.58 to 3.33 mmol/L)&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2 or more risk factors (10-year risk &le;20 percent)&Delta;",
"      </td>",
"      <td>",
"       &le;130 mg/dL (3.36 mmol/L)",
"      </td>",
"      <td>",
"       &ge;130 mg/dL (3.36 mmol/L)",
"      </td>",
"      <td>",
"       10-year risk 10 to 20 percent: &gt;130 mg/dL (3.36 mmol/L) 10-year risk &lt;10 percent: &ge;160 mg/dL (4.13 mmol/L)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0 to 1 risk factor&loz;",
"      </td>",
"      <td>",
"       &le;160 mg/dL (4.13 mmol/L)",
"      </td>",
"      <td>",
"       &ge;160 mg/dL (4.13 mmol/L)",
"      </td>",
"      <td>",
"       &ge;190 mg/dL (4.91 mmol/L); LDL-cholesterol lowering drug optional at 160 to 189 mg/dL (4.13 to 4.88 mmol/L)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * CHD risk equivalents defined in text. 10-year risk defined by Framingham risk score (see text).",
"     <br>",
"      &bull; Some authorities recommend use of LDL-cholesterol lowering drugs in this category if LDL-cholesterol &lt;100 mg/dL (2.58 mmol/L) cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-cholesterol (eg, nicotinic acid or fibrate). Clinical judgement may also call for deferring drug therapy in this subcategory.",
"      <br>",
"       &Delta; Risk factors that modify LDL-cholesterol goals include cigarette smoking; hypertension (BP 140/90 mmHg or on antihypertensive medication); low HDL-cholesterol (&lt;40 mg/dL [1.03 mmol/L]); family history of premature CHD (CHD in male first degree relative &lt;55 years or CHD in female first degree relative &lt;65 years); age (men 45 years; women 55 years). HDL-cholesterol 60 mg/dL (1.55 mmol/L) counts as a negative risk factor; its presence removes one risk factor from the total count.",
"       <br>",
"        &loz; Almost all people with 0 to 1 risk factor have a 10-year risk &lt;10 percent; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Adult Treatment Panel III at file://www.nhlbi.nih.gov/.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed modifications of ATP III LDL-cholesterol goals and cutpoints for therapeutic lifestyle changes and drug therapy in different risk categories",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk category",
"       </td>",
"       <td class=\"subtitle1\">",
"        LDL goal",
"       </td>",
"       <td class=\"subtitle1\">",
"        LDL level at which to initiate therapeutic lifestyle changes",
"       </td>",
"       <td class=\"subtitle1\">",
"        LDL level at which to consider drug therapy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         High risk:",
"        </strong>",
"        Coronary heart disease (CHD) or CHD risk equivalent (10-year risk &gt;20 percent)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;100 mg/dL (2.58 mmol/L); optional goal &lt;70 mg/dL (1.82 mmol/L) in very high risk",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;100 mg/dL (2.58 mmol/L)",
"        <sup>",
"         &loz;",
"        </sup>",
"        &ge;",
"       </td>",
"       <td>",
"        100 mg/dL (2.58 mmol/L)",
"        <sup>",
"         &sect;",
"        </sup>",
"        ; &lt;100 mg/dL (2.58 mmol/L) consider drug options",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Moderately high risk:",
"        </strong>",
"        2 or more risk factors (10-year risk 10 to 20 percent)",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;130 mg/dL (3.36 mmol/L)",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;130 mg/dL (3.36 mmol/L)",
"        <sup>",
"         &loz;",
"        </sup>",
"        &ge;",
"       </td>",
"       <td>",
"        &ge;130 mg/dL (3.36 mmol/L); 100 to 129 mg/dL consider drug options",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Moderate risk:",
"        </strong>",
"        2 or more risk factors (10-year risk &lt;10 percent)",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;130 mg/dL (3.36 mmol/L)",
"       </td>",
"       <td>",
"        &ge;130 mg/dL (3.36 mmol/L)",
"       </td>",
"       <td>",
"        &ge;160 mg/dL (4.13 mmol/L)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Lower risk:",
"        </strong>",
"        0 to 1 risk factor**",
"       </td>",
"       <td>",
"        &lt;160 mg/dL (4.13 mmol/L)",
"       </td>",
"       <td>",
"        &ge;160 mg/dL (4.13 mmol/L)",
"       </td>",
"       <td>",
"        &ge;190 mg/dL (4.91 mmol/L); 160 to 189 mg/dL consider drug options",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * When LDL lowering drug therapy is given, it is advised that the intensity of therapy be sufficient to achieve at least a 30 to 40 percent reduction in LDL levels.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     CHD risk equivalents include noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease), and diabetes. Ten-year risk defined by modified Framingham risk score.",
"     <br/>",
"     &Delta; Very high risk favors the optional LDL goal of &lt;70 mg/dL (1.82 mmol/L) and, in patients with high triglycerides, non-HDL cholesterol goal of &lt;100 mg/dL.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     &ge; Any individual at high or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, hypertriglyceridemia, low HDL-cholesterol [&lt;40 mg/dL (1.04 mmol/L)], or metabolic syndrome is a candidate for therapeutic lifestyle changes to modify these risk factors independent of LDL level.",
"     <br/>",
"     &sect; If baseline LDL is &lt;100 mg/dL (2.58 mmol/L), institution of an LDL lowering drug is an option. This can be combined with a fibrate or nicotinic acid if a high-risk person has hypertriglyceridemia or low HDL (&lt;40 mg/dL (1.04 mmol/L).",
"     <br/>",
"     &yen; Risk factors that modify LDL goals include cigarette smoking; hypertension (BP &ge;140/90 mmHg or on antihypertensive medication)s; low HDL-cholesterol (&lt;40 mg/dL [1.03 mmol/L]); family history of premature CHD (CHD in male first degree relative &lt;55 years or CHD in female first degree relative &lt;65 years); age (men &ge;45 years; women &ge;55 years). HDL-cholesterol &ge;60 mg/dL (1.55 mmol/L) counts as a negative risk factor; its presence removes one risk factor from the total count.",
"     <br/>",
"     &Dagger; Optional LDL goal &lt;100 mg/dL (2.58 mmol/L).",
"     <br/>",
"     &dagger; For moderately high risk persons with LDL of 100 to 129 mg/dL (2.58 to 3.35 mmol/L) at baseline or after lifestyle changes, initiation of an LDL lowering drug to achieve an LDL &lt;100 mg/L is an option.",
"     <br/>",
"     ** Almost all people with 0 to 1 risk factor have a 10-year risk &lt;10 percent; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002; 106:3143; with modifications from Grundy SM, Cleeman JI, Merz CN, et al, Circulation 2004; 110:227.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definition of \"very high risk\" in NCEP guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Established coronary heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        PLUS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Multiple major risk factors (especially diabetes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &nbsp;OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Severe and poorly controlled risk factors (especially continued smoking)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &nbsp;OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Multple risk factors of the metabolic syndrome (especially triglycerides &ge;200 plus non-HDL-C &ge;130 plus HDL-C &lt;40)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &nbsp;OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Acute coronary syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Grundy SM, Cleeman JI, Merz NB, et al. Circulation 2004; 110:227.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16830=[""].join("\n");
var outline_f16_27_16830=null;
var title_f16_27_16831="SCD and risk factors in HCM";
var content_f16_27_16831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sudden cardiac death and risk factors in hypertrophic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 479px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier estimates of the proportions of patients surviving from sudden cardiac death, appropriate ICD discharge, or resuscitated ventricular fibrillation in relation to number of risk factors in patients with obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Elliott, PM, Gimeno, JR, Tome, MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27:1933. Copyright &copy; 2006 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_27_16831=[""].join("\n");
var outline_f16_27_16831=null;
